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Effective case management of malaria is hampered by the spread of parasite resistance to non-
artemisinin antimalarials. To counteract the impact of drug resistance, the World Health 
Organization (WHO) has endorsed artemisinin-based combination therapy (ACT) as the first-
line treatment for uncomplicated Plasmodium falciparum malaria. Currently recommended 
ACTs are artemether-lumefantrine, artesunate plus amodiaquine, artesunate plus mefloquine, 
artesunate plus sulfadoxine-pyrimethamine and dihydroartemisinin-piperaquine.  
 
This study sought to review evidence of the efficacy and safety of different non-artemisinin 
antimalarials in combination with artesunate, artemether or dihydroartemisinin for the 
treatment of uncomplicated P. falciparum malaria in non-pregnant adults and children. The 
search for randomized controlled trials (RCTs) was conducted in the Cochrane Central 
Register for Controlled Trials (CENTRAL), MEDLINE, EMBASE and in ClinicalTrials.gov 
in January 2009. The eligibility and the methodological quality of trials were assessed and 
data were extracted, using standard forms. Data were captured and analyzed in Review 
Manager Software, versions 4.2 and 5.0. The outcomes assessed were: treatment failure, fever 
and parasite clearance time, calculating the relative risk (RR) and a weighted mean difference 
(WMD) with a 95% confidence interval and p-values, indicating statistical significance at 
0.05. 
 
Thirty-seven trials with 6862 participants were included. Artesunate combined with 
amodiaquine had a statistically significant lower risk of treatment failure compared to the 
combination of artesunate with sulfadoxine-pyrimethamine (RR=0.57, 95% CI [0.33, 0.97], 
 xv 
p=0.04, seven trials, N=1341). In addition, treatment with artesunate plus mefloquine was 
significantly associated with a lower risk of treatment failure compared to artesunate plus 
azithromycin (RR=0.04, 95% CI [0.00, 0.64], p=0.02, one trial, N=54). There was no 
significant difference when either mefloquine or atovaquone-proguanil were combination 
partners with artesunate (RR=2.6, 95% CI [0.93; 7.24], p=0.07, one trial, N=1066). When 
artesunate was combined with chloroquine, primaquine or azithromycin and compared with 
artesunate monotherapy, there was no statistically significant difference in the risk of 
unadjusted treatment failure. Each of these comparisons had one trial each.  Artesunate plus 
chloroquine was quicker at clearing fever compared to artesunate plus sulfadoxine-
pyrimethamine (WMD= -7.20, 95% CI [-12.53, -1.87], one trial, N=132).  
 
Few trials adequately reported adverse events. There was no significant difference observed in 
the risk of adverse events between artesunate plus amodiaquine compared with artesunate 
monotherapy, however, adverse events were significantly less in artesunate plus amodiaquine 
compared to artesunate plus methylene-blue. Artesunate plus amodiaquine on the other hand 
had significantly more adverse events reported compared to artesunate plus sulfadoxine-
pyrimethamine.  
 
The findings of this study support the implementation of artemisinin-based combination 
therapy for the treatment of uncomplicated malaria. Most crucially, this review found a greater 
advantage of combining amodiaquine with artesunate compared to sulfadoxine-
pyrimethamine. The efficacy of artesunate plus mefloquine was superior to that of artesunate 
plus azithromycin. Furthermore, the combination of artemisinins with chloroquine, primaquine 
and azithromycin has shown very low efficacy and these combination therapies should not be 
 xvi 
recommended. The reporting of efficacy was not standardized as many trials did not 
differentiate between re-infections and recrudescences. Adverse events were also not 
adequately reported.  
 1 
CHAPTER 1: INTRODUCTION 
 
1.1 The burden of malaria 
Malaria remains one of the most devastating parasitic infections and a major cause of 
morbidity and mortality in tropical and sub-tropical regions of the world. It is closely 
intertwined with underdevelopment and flourishes in situations of social and environmental 
crisis and weak health systems (WHO, 2009). Malaria disease is due to blood infection by 
protozoan parasites of the genus Plasmodium, which are transmitted from one human to 
another by female Anopheles mosquitoes. Rarely transmission can be through accidents such 
as blood transfusion or through the placenta from an infected mother to her unborn child. 
There are four well known species of Plasmodium that cause malaria in humans; Plasmodium 
falciparum, P. vivax, P. ovale and P. malariae. The other Plasmodium parasite previously 
thought not to cause malaria in humans, P. knowlesi has also been identified as one of the 
causes of naturally acquired malaria in humans. Almost all severe disease and deaths are due 
to P. falciparum infections (Gillies, 1993; Gupta et al., 1994; Breman, 2001).  
 
It is estimated that 2.2 billion people are exposed to the threat of malaria globally and there are 
about 515 (range 300-660) million clinical attacks per year attributed to P. falciparum. Most 
clinical events of malaria are concentrated in Africa, about 70.9%, 23.1% in South-East Asia, 
2.9% in the Western Pacific region, 2.3% in the Eastern Mediterranean, 0.7% in America and 
0.1% in Europe (Snow et al., 2005). In high transmission areas, pregnant women and children 
under the age of five years bear the heaviest burden of malaria compared to non pregnant 
adults (Murphy and Breman 2001; Breman 2001; Steketee et al., 2001). 
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The world malaria report (WHO, 2009) estimated that malaria accounted for an estimated  863 
000 deaths in 2008, with 89% of those occurring in Africa, while South East Asia and the 
Eastern Mediterranean account for 4.64 and 6% of the malaria deaths, respectively. The 
Western Pacific region has 0.35% of the total malaria deaths whereas the Americas has 0.12%. 
Europe has the lowest burden of malaria, with no deaths recorded (WHO, 2009).  In highly 
endemic areas, malaria is considered to be the main cause of death in children and in pregnant 
women (Murphy and Breman 2001; Steketee et al., 2001). 
 
Malaria poses an economic burden and is related to poverty. Geographically, malaria and 
poverty are both concentrated within the same boundaries. Malaria-endemic countries are not 
only poorer than non-malarious countries but they also have lower rates of economic growth. 
In 1995, the gross domestic product (GDP) per capita in malarious countries was estimated to 
be US$1.526 compared to US$8.268 in countries without intensive malaria transmission 
(Gallup and Sachs, 2001). Malaria impacts on trade, tourism, direct foreign investments and is 
associated with high fertility rates, which in turn reduces the likelihood of schooling in poor 
households (Sachs and Milaney, 2002). It is estimated that children already attending school 
miss 4.3 to 11% of school days due to malaria (Leighton and Foster, 1993) and up to 50% of 
medically related school absences are attributed to malaria (Brooker et al., 2000). 
Absenteeism increases failure rates, repetition of school years and drop out rates (Sachs and 
Malaney, 2002). An African family may spend up to 25% of their income on malaria 
prevention and treatment and African countries may lose up to US$12 billion in lost GDP per 




1.2 The life cycle of Plasmodium parasites and Anopheles mosquitoes 
1.2.1 The Plasmodium parasite life cycle in the human host 
Although the human malaria parasite species are closely related, there are major differences 
among them with regards to the severity of their infection and their geographical distribution. 
Infection caused by P. vivax is the most widely distributed and the most common in temperate 
regions of the world. P. falciparum is the most clinically dangerous and the most widespread 
in sub-Saharan Africa and throughout the world's tropics. In South Africa, the most prevalent 
plasmodium species is P. falciparum (Snow et al., 2003). P. ovale malaria is more common in 
West Africa and P. malariae has a similar geographic range as P. falciparum, although it is 
much less prevalent and occurs in more restricted zones. Infection with P. vivax may relapse 
months after the initial infection and if inadequately treated, P. malariae may persist for 
several years (Garnham, 1988; Oaks, 1991). P. malariae and P. knowlesi are difficult to 
distinguish microscopically, leading to misidentification of the two species (Cox-Singh et al., 
2008). 
 
Malaria parasites have a complex life-cycle involving vertebrate hosts and mosquito vectors as 
shown in figure 1.1. The life cycle starts when an infected Anopheles mosquito takes a blood 
meal, sporozoites are inoculated into the human blood, 15-20 sporozoites are injected at a bite 
(Bruce-Chwatt, 1985; Oaks, 1991). Once injected, the sporozoites infect the liver, entering the 
hepatocytes where they begin to divide into hepatic schizonts. This stage is called tissue 
schizogony. Each infected hepatic schizont ruptures and releases merozoites, which then 
invade erythrocytes or red blood cells (RBC). Approximately 30 000 merozoites are released 
after 5-6 days by each infected hepatocyte, a single schizont rupture releases 32 merozoites 
(Bruce-Chwatt, 1985; Oaks, 1991). 
 4 
In the erythrocytes, the merozoites develop into early trophozoites, which are ring shaped, 
vacuolated and uni-nuclealated, these trophozoites consume haemoglobin in RBCs (Mauritz et 
al., 2009). The infected erythrocytes are eventually lysed by merozoites, which subsequently 
invade other erythrocytes, starting a new cycle of schizogony. The parasite burden expands 
logarithmically by approximately 10-fold per cycle. All the clinical symptoms of malaria 
(such as fever, malaise, anaemia) are associated with this multiplication of blood stage 












Figure 1.1: The life cycle of Plasmodium parasites in the human host and the mosquito vector. 
Adapted from White (2004).  
 
After several cycles, some merozoites develop into gametocytes, the sexual forms of malaria 
parasites, which do not cause symptoms but are infective to mosquitoes. Gametocyte 
development continues in the human host over a period of approximately 10 days, 
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encompassing five morphologically defined gametocyte stages, ending with the formation of 
mature male and female gametocytes. In the first three stages, the sexual parasites are 
sequestered and they are potentially susceptible to drugs used to treat asexual stage parasites. 
In stage four, they re-enter the circulation and by stage five, they are resistant to most drugs 
(Bruce-Chwatt, 1985; Oaks, 1991). 
 
1.2.2 The Plasmodium parasite life cycle in the mosquito vector 
There are more than 400 species of Anopheles worldwide, however, only about 60 are vectors 
of malaria parasites and only 30 are vectors of major importance (Bruce-Chwatt, 1985). In a 
particular region, only one or a few Anopheles mosquito species serve as the predominant 
malaria vectors. The most efficient vectors for P. falciparum in the Afrotropical region (Sub-
Saharan Africa, Madagascar, Seyhelles and Mauritius) are in the A. gambiae complex (which 
includes A. gambiae, A. arabiensis, A. melas, A. merus, A. bwambae and A. quadriannulatus) 
and A. funetus (Breman, 2001). A. gambiae has the highest rate of sporozoite development and 
exists in frost free regions or where the temperature remains above 5°C (Leeson, 1931; Gillies 
and De Meillion, 1968).  
 
Among the A. gambiae complex, A. gambiae sensu stricto is the most important vector and it 
is probably the world’s most efficient malaria vector. It bites humans both indoors 
(endophagic) and outdoors (exophagic), it rests mainly indoors (endophilic) but it may also 
rest outdoors (exophilic) (Service, 1996). The adult female Anopheles mosquitoes require 
protein from blood meals for their eggs to mature. They generally feed only between sunset 
and dawn and they prefer to feed near the ground level often selecting to feed on the lower leg 
rather than the arms and the upper body. About 81% of bites by A. arabiensis occur on the 
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ankles or feet. A. arabiensis has similar breeding and biting habits to A. gambiae s.s., except 
that the mosquito tends to occur in drier areas and it is more likely to bite cattle and rest 
outdoors (Service, 1996). 
 
The mosquito undergoes four stages of growth, namely egg, larva, pupa, and adult. Adult 
females mate once and store the sperm. The female may deposit a total of 200 to 1,000 eggs in 
three or more batches (Morrow, 2007). The actual egg production is dependent on blood 
consumption. After hatching, anopheline larvae lie along the water-air interface, where they 
feed on organisms along the surface film. Adult mosquitoes develop from the pupa stage 
within 2 to 4 days. An adult mosquito will emerge from the egg stage in 7 to 20 days, 
depending on the species of mosquito and environmental conditions (Oaks, 1991).  
 
Female anopheline mosquitoes can survive at least a month under favorable conditions of high 
humidity and moderate temperatures. That is sufficient time for them to take a blood meal, for 
the parasite to develop, and the mosquito to take another blood meal and thus transmit the 
parasite to a second human host (Oaks, 1991). When mature gametocytes are taken up by a 
mosquito as part of a blood meal, sexual development continues in the mosquito gut; the male 
gametocyte undergoes three rounds of mitosis leading to the formation of eight highly motile 
haploid gametes. The process is called exflagellation. Female gametocytes enlarge to form 
female gametes. Fertilization of a single male and female gamete forms a diploid zygote, 
which then differentiates into a motile ookinete (Morrow, 2007). After traversing the 
peritrophic matrix, which is a chitin-containing extracellular layer surrounding the blood 
bolus, the ookinetes cross the midgut epithelium and lodge beneath the basal lamina facing the 
mosquito body cavity (hemocoel). During the next 10-15 days (depending on the parasite 
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species and temperature), they differentiate into mature oocysts. Each oocyst produces 
thousands of sporozoites that are released into the hemocoel and invade the salivary glands. 
When the mosquito takes a blood meal, sporozoites leave with the saliva which includes an 
anti-coagulant, infecting the new vertebrate host where the asexual part of the life cycle takes 
place (Bruce-Chwatt, 1985; Oaks, 1991).  
 
1.3 The transmission of malaria 
Malaria is governed by a large number of environmental factors, which affect its distribution, 
seasonality and transmission intensity (Snow et al., 1999). The environmental drivers are 
determined by the sensitivity of anopheline vectors and its particular plasmodium parasite to 
climate and thus latitude and elevation (Macdonald, 1956; Molyneux, 1988; Oaks, 1991).   
 
Ambient temperature plays a major role in the cycle of both the malaria parasite and its vector. 
The development of the parasite within the mosquito (sporogonic cycle) is dependant on 
temperature. On average, the sporogonic cycle takes about 9-10 days at temperatures of 28°C 
and stops at temperatures below 16°C. The daily survival of the vector is dependant on 
temperature as well. Generally, at temperatures between 16 and 36°C, the daily survival is 
about 90%. This survival drops rapidly at temperatures above 36°C. The highest propotion of 
vectors surviving the incubation period is observed at temperatures between 28 and 32°C 
(Mcdonald, 1956; Oaks, 1991) 
 
Rainfall provides breeding sites for mosquitoes to lay their eggs. It is also related to humidity, 
thus affecting mosquito survival. Though flooding often causes destruction of breeding sites 
and a temporary reduction of vectors, it never eliminates the vectors. A. gambiae mosquitoes 
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breed readily in large and small collections of sun-exposed still water, which exist throughout 
tropical Africa (Mcdonald, 1956; Oaks, 1991). In regions where temperature is high but 
rainfall is limiting, mosquito populations increase rapidly at the onset of rain because of short 
development cycles. In areas where the temperature is low, mosquito populations increase 
slowly at the onset of rain, and parasite development takes a long time (Craig et al., 1999).  
 
Regions can therefore be classified according to the suitability of conditions for transmission 
and disease patterns. There are regions with perennial transmission, where climatic conditions 
are always suitable for transmission and the disease is endemic. Some regions have seasonal 
malaria transmission, where conditions become most suitable during a certain period in a 
given year. There are epidemic regions, where conditions are unstable and suitable for 
transmission on an irregular basis and there are malaria free regions, where conditions are 
always unsuitable for malaria transmission (Craig et al., 1999).  
 
The level of malaria transmission in a given area is measured using a number of malariometric 
indexes. These include the entomologic inoculation rate, vector capacity, reproductive rate, 
parasite prevalence and the disease incidence. The entomologic inoculation rate is expressed 
as the number of infective mosquito bites per person per unit time. The reproductive rate is the 
mean number of secondary cases (infections) that result from a single infective case 
introduced in a susceptible population (Martens, 1999). Vector capacity is defined as the 
average number of inoculations with a specified parasite, originating from one case of malaria 
in unit time, which the population would distribute to man if all the vectors biting the case 
became infected (Garrett-Jones, 1964). Parasite prevalence is defined as the proportion of a 
sampled population that is confirmed positive for malaria parasites, canonically by identifying 
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immature “ring stage” trophozoites in stained blood film slides (Gillies, 1993). Lastly, disease 
incidence is measured as the number of new infections in a defined period.  
 
1.4 The symptoms of infection and immunity to malaria 
1.4.1 The symptoms of malaria infection 
The early signs and symptoms of uncomplicated malaria tend to be non-specific and they often 
resemble those of common viral infections. Common manifestations include fever, chills, 
malaise, abdominal discomfort and mild anaemia. Fever patterns are usually described with 
spikes every two days in P. falciparum. Other common symptoms include rigors, headache, 
cough, diarrhoea, dizziness, nausea, vomiting, sweating and weakness (Snow et al., 1999). 
 
In a small proportion of P. falciparum infections, unrestricted parasite multiplication leads to 
heavy parasite burdens, leading to severe malaria. The major complications of severe malaria 
include cerebral malaria, coma or repeated convulsions, respiratory distress, pulmonary 
oedema, acute renal failure, severe anaemia, acidosis, hypoglycemia and hyperlactataemia. 
Any of these complications can develop rapidly and progress to death within hours or days 
(WHO, 2000; Murphy and Breman, 2001; Dzeing-Ella et al., 2005). However, the relationship 
between transmission intensity and disease outcome is not simple and straight forward and 
depends, among other things, on the immune status of the human host.  
 
1.4.2  Immunity to malaria 
People living in endemic areas appear to acquire some degree of immunity to malaria as a 
result of repeated exposure to P. falciparum parasites from infancy (Bunn et al., 2004). This 
immunity is acquired slowly, however, a state of sterile immunity against all infections is 
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never attained (White, 2004). Immunity is acquired at a variable rate and it is species-, stage-, 
strain- and variant-specific (Wipasa et al., 2002). Immunity to malaria is often rapidly lost 
when an individual moves away from endemic areas (Keenihan et al., 2003). In low 
transmission areas, adults do not get repeated exposure to malaria parasites from infancy, thus 
the risk of the severity of infection is equivalent among all age groups (Snow et al., 1999). In 
non-immune individuals, the majority of malaria infections are symptomatic and they often 
occur a day or two before parasites are detectable in the blood (White, 2004). Individuals in 
endemic areas often tolerate parasites without developing sysmptoms (Artavanis-Tsakonas et 
al., 2003). Epidemiological studies (Snow et al., 1997) have shown that under conditions of 
intense, perennial, stable transmission, the burden of morbidity and mortality is concentrated 
among the youngest age groups which are children under the age of five years. 
 
1.4.2.1 Immunity in infants and young children 
Young infants in malaria endemic areas are often protected from P. falciparum infection early 
in life, mainly as a result of trans-placentally acquired maternal antibodies (Akanmori et al., 
1995). When infected, their infections tend to be of very low parasite density, frequently at the 
lower limit of detection by microscopy (Wagner et al., 1998). They also tend to be 
asymptomatic and infection is spontaneously cleared within four weeks (Franks et al., 2000). 
Achidi and co-workers investigated the duration of antibodies in infants in an endemic area in 
Nigeria and found that the concentration of maternal antibodies fell to minimal levels by the 
age of four months and infant antibody titres began to rise from about six months of age, 
following malaria exposure (Achidi et al., 1995). The passive transfer of antibodies from 
mother to child continues post-natally via breastfeeding as antimalarial antibodies are 
detectable in human breastmilk. Antibodies from breastmilk are believed to act only locally 
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within the gut as the bulk of breastmilk immunoglobulin is degraded in the intestines and very 
small amounts are absorbed in an active form into the systematic circulation (Leke et al., 
1992).  
 
1.4.2.2 Immunity in pregnant women 
In pregnancy, malaria infection is recognized as the major public health problem throughout 
the world, causing serious complications especially in women who have a low level of 
acquired immunity before pregnancy (Nahlen, 2000). Its frequency and severity are greater 
during pregnancy than before pregnancy and among pregnant women than in non-pregnant 
ones (Diagne et al., 2000). The impact of malaria on pregnant women varies according to the 
intensity of transmission; this is also true for the level of immunity acquired by the mother 
(Cot and Deloron, 2003).  
 
The most severe malaria infections in pregnant women are caused by Plasmodium falciparum. 
The other three human malaria parasites contribute to fewer infections and more moderate 
disease and relatively few deaths (Mendis et al., 2001; Steketee et al., 2001). However, a few 
reports of adverse consequences due to P. vivax in pregnancy exist (Nosten et al., 1999). 
Malaria infection in pregnancy increases the chance of maternal anaemia, abortion, stillbirths, 
premature birth, intrauterine growth retardation (IUGR) and low birth weight (LBW), which is 
defined as the weight <2500g, which is the greatest risk factor for neonatal mortality (Nahlen, 
2000). These occur with great frequency in endemic areas and they threaten lives of both 




1.5 Malaria control 
In general, malaria is a preventable and curable disease. The control of malaria infection has 
traditionally relied on two arms; controlling the anopheline mosquito vector and effective case 
management. A long hoped for third arm; an effective malaria vaccine has not yet 
materialized. For vector control the WHO’s global malaria programme recommends indoor 
residual spraying (IRS) with an insecticide, where applicable dichlorodiphenyltrichloroethane 
(DDT), and the distribution of insecticide-treated bed nets (ITNs) to populations at risk as 
means to reduce and eliminate malaria transmission. For parasite control, prompt diagnosis of 
malaria cases and treatment with effective antimalarials is recommended (WHO, 2006a). 
 
1.5.1 Malaria vector control 
Vector control employs environmental management targeted at the larval stages of malaria 
vectors, prevention of human-vector contact via the use of insecticide-treated bed nets and 
indoor residual spraying with insecticides to reduce vector density. Chemicals used in vector 
control strategies broadly fall into five categories. The first are petroleum oils, which are 
sprayed into water thus forming a film which prevents the larvae and the pupae from breathing 
through the water surface. The natural constituents of flowers like pyrethrum, pyrethrins and 
synthetic derivatives like pyrethroids form another group. Lambda-cyhalothrin is also included 
in this group. Organochlorines which include benzinehexachloride (BHC), DDT and dieldrin, 
organophosphates such as malathion and temephos and carbamates, which include bendiocarb 





1.5.1.1 Environmental management for malaria vector control 
Since the role of Anopheles mosquitoes was recognized in malaria transmission, malaria 
control experts also recognized the value of reducing mosquito larval habitats to eliminate 
malaria transmission (Bruce-Chwatt, 1985). The concept of modifying vector habitat to 
discourage larval development is generally referred to as environmental management (Walker, 
2002).  
 
Environmental management is used to reduce the number of breeding sites and therefore the 
overall population of vector species. It includes larviciding, drainage, flushing, filling and 
rendering river and lake margins unsuitable for Anophelene breeding (Shiff, 2002). However, 
in rural settings it is impractical to suggest source reduction as the only effective control effort 
for anophelines, particularly because breeding sites may be numerous and vectors are 
opportunists. Furthermore, their populations expand during rainy spells and they breed in a 
variety of situations, thus under such conditions attempting to limit the extent of suitable 
breeding habitats may not be successful. Nevertheless, when properly executed and 
maintained, its sustainability is relatively easy, particularly in urban areas (Killeen et al., 
2004). Environmental management methods should be seriously considered in agricultural 
systems and in man-made environments it should be the first-line of defense in reducing the 
risk of malaria transmission (Najera and Zaim, 2002).  
 
1.5.1.2 The use of insecticide-treated bed nets for malaria vector control 
An insecticide-treated bed net is a mosquito bed net that repels, disables and/or kills 
mosquitoes that come into contact with the insecticide on the bed net material. There are two 
categories of insecticide-treated bed nets; the conventionally treated and the long-lasting 
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insecticidal treated bed nets. Conventionally treated bed nets are the ones treated by dipping in 
an insecticide. The longer-lasting insecticide treated bed nets are factory-treated mosquito bed 
nets in which the insecticide is incorporated within or bound around the fibres of the netting 
material (WHO, 2007).   
 
A treated mosquito bed net provides personal protection against malaria to the individual 
using it by acting as both physical and chemical barrier and therefore increases the efficacy of 
the mosquito bed net. The physical barrier prevents access by mosquitoes and reduces human-
vector contact while the chemical barrier is provided by the insecticides and can kill adult 
mosquitoes directly or indirectly, further reducing contact with the human host (WHO, 2007). 
Although insecticide-treated bed nets are widely viewed as devices for personal protection, 
they may have community-wide effects as well. When full coverage is achieved, insecticide-
treated bed nets are associated with reduced all-cause child mortality in sub-Saharan Africa 
(Binka et al., 1998; Howard et al., 2000; Lengeler, 2004; Gamble et al., 2006). This is because 
insecticide-treated bed nets can kill adult mosquitoes directly or force them to take longer 
routes in search of vertebrate blood. Overall, insecticide-treated bed nets have been shown to 
reduce the incidence of clinical attacks of malaria by an average of 50% in different 
epidemiological settings in Asia and Africa (Choi et al., 1995).  
 
1.5.1.3 Indoor residual spraying for malaria vector control 
Indoor residual spraying is the application of long-acting chemical insecticides on the walls 
and roofs of all houses and domestic animal shelters in a given area, in order to kill the adult 
vector mosquitoes that land and rest on these surfaces, it reduces the life span of mosquitoes 
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so that they are unable to transmit malaria parasites from one person to another (WHO, 
2006a). 
 
Indoor residual spraying became the mainstay of malaria control in the world following the 
availability of DDT and other insecticides in the 1940s. Its effectiveness against indoor resting 
mosquitoes led to the adoption of the Global Malaria Eradication Programme in 1955. The 
efforts of the Global Malaria Eradication Programme contributed significantly in reducing the 
burden of malaria; in the United States, Europe and in the former Soviet Union, malaria was 
completely eliminated. South East Asia, India and South America experienced a significant 
reduction in disease incidence. In Africa, malaria eradication was piloted from the 1950s to the 
1970s in Benin, Burkina Faso, Burundi, Cameroon, Kenya, Liberia, Madagascar, Nigeria, 
Rwanda, Senegal, Uganda and the United Republic of Tanzania. These projects demonstrated 
that malaria was highly responsive to indoor-residual spraying, the vector population was 
decreased but transmission could not be interrupted, this led to a conclusion that malaria 
eradication was not possible and was substituted with malaria control (Najera, 1999). Only 
South Africa, Botswana, Namibia, Zimbabwe and Swaziland successfully sustained large 
scale malaria control operations based on indoor-residual spraying with insecticides (Mabaso 
et al., 2004).  
 
Recently, there has been a renewed interest in scaling up indoor-residual spraying along with 
other vector control strategies (WHO, 2006a). It is noted, however, that even with the most 
effective vector control measures, the numbers of clinical cases remains substantial and 
effective case management is required for limiting morbidity, mortality and the economic 
impact of malaria (Winstanley et al., 2004).  
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1.5.2 Malaria parasite control 
1.5.2.1 Effective case management for parasite control 
Effective case management is a fundamental and an indispensable element for malaria control. 
It aims to limit the duration of the disease, prevent progression of mild to severe or 
complicated malaria, prevent death from severe malaria, prevent transmission of parasites and 
minimize the risk of selection and spread of drug resistance. Determinants of effective case 
management involve the early and accurate diagnosis of malaria as well as availability, 
affordability and accessibility of safe and effective antimalarials. Early and accurate diagnosis 
of malaria depends on high sensitivity and specificity of diagnostic tools and if implemented 
effectively, it will help to reduce unnecessary use of antimalarials (WHO, 2009).  
 
Methods used for parasitological diagnosis are light microscopy and rapid diagnostic tests 
(Tagbor et al., 2008). In addition, there are techniques used to detect the parasite’s 
deoxyribonucleic acid (DNA) based on polymerase chain reaction (PCR), which are highly 
sensitive and very useful for detecting mixed infections, in particular, at low parasite densities 
(Tagbor et al., 2008). PCR techniques are also useful for studies on drug resistance and other 
specialized epidemiological investigations but are not generally available in malaria endemic 
areas. According to the WHO guidelines, the results for parasitological diagnosis should be 
available within a short time (less than two hours) after presentation, if this is not possible, the 
patient must be treated on the basis of clinical diagnosis (WHO, 2006b).  
 
There are different classes of antimalarials that act on the different stages of the parasite. The 
anti-plasmodial action of sulfonamides and sulfones was reported as early as 1937 
(Wernsdorfer and Trigg, 1988) and they act on all multiplying stages in the parasite’s life-
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cycle. Their activity is limited by their slow and short lasting action and the need for high 
doses that may be toxic. Longer acting compounds like sulfadoxine and sulfadiazine have 
since been developed and are used in combination with dihydrofolate reductase inhibitors. 
Dihydrofolate reductase inhibitors like pyrimethamine and trimethoprim only affect the 
schizont stage of the parasite and they disrupt the folate pathway (Wernsdorfer and Trigg, 
1988). Blood schizontocides such as chloroquine (CQ), Quinine (Q), mefloquine (MQ) and 
amodiaquine (AQ) only have effects on the erythrocytic stages of malaria parasites 
(Wernsdorfer and Trigg, 1988). 
 
There are also antibiotics that have been used for the treatment of malaria. The first reports of 
antimalarial effect of antibiotics appeared in 1949 (Wernsdorfer and Trigg, 1988), when 
chlorotetracycline was found to be effective against avian and human malaria parasites. The 
antibiotics that were of potential value to malaria chemotherapy included chlorotetracycline, 
oxytetracycline, chloroamphenicol, clindamycin, erythromycin and doxycycline. Their 
schizontocidal and liver-stage activity has been shown, but their effects were slow to be 
manifested in comparison to other drugs such as chloroquine (Wernsdorfer and Trigg, 1988).  
 
1.6 Challenges to malaria vector and parasite control 
Despite the efficacy and effectiveness of interventions, malaria control is made difficult by 
several administrative and technical problems. Deficiencies in social structure, economic 
conditions, communication, administrative systems and health organization have posed 
difficulties in malaria control (Najera, 1999). Although the effectiveness of some control 
strategies has been proven, inadequate implementation, differing political and power views 
often come on the way of successful malaria control and elimination (Omari, 1988).  
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The main technical problems include, among other factors, insecticide and antimalarial 
resistance. The development and spread of insecticide resistance decreases the efficacy of 
interventions such as IRS and antimalarial resistance in parasites hinders effective 
management of malaria cases and contributes to the transmission of the disease.   
 
1.6.1 The challenges of insecticide resistance in vector control 
Insecticide resistance is defined as the ability of an organism to tolerate doses of a toxicant 
that would prove lethal to a majority of organisms in a normal population of the same species 
(Hemingway and Ranson, 2000). Resistance is genetically inherited and when an insecticide is 
applied, resistant organisms have a higher probability of surviving over susceptible ones, 
which increases the resistance gene and thus the resistant population over time (Coleman and 
Hemingway, 2007). 
 
Two major mechanisms of resistance in mosquitoes have been shown, which are increased 
metabolism of insecticide which reduces the effective insecticide dose available at the target 
site and reduced target site sensitivity which leads to ineffective binding of a given dose of 
insecticide (Hemingway et al., 2004). Metabolic resistance mechanisms can be attributed to 
the enzyme glutathione-S- transferase (GST) and target site resistance can be attributed to 
nerve insensitivity governed by the knockdown resistance gene (kdr gene) (Chandre et al., 
1999). Insecticides such as DDT and permethrin may also influence behavioral changes in 
insects by reducing the rate of mosquito entry into houses, by causing them to exit early from 
the house or by inducing a shift in biting times. The insecticide’s penetration may be reduced 
by the alteration or thickening of mosquito’s cuticle (Hemingway et al., 2004).  
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During the Global Malaria Eradication Programme in the 1950s and the 1960s, dieldrin 
resistance was recorded among most A. gambiae s.l. populations in Africa. In contrast, only a 
few cases of DDT resistance were reported at that time. The first report involved A. gambiae 
s.s. in Burkina Faso in 1967 and was attributed to the use of DDT in cotton pest control. After 
that, it was also recorded among A. arabiensis from Senegal (Brown and Pal, 1973; Mouchet, 
1988; Lines, 1988). Resistance to DDT became wide-spread in the early 1970s and recently, it 
has been observed in Ghana, South Africa, Kenya and Cote-d‘Ivore (Ranson et al., 2000; 
Hargreaves et al., 2003; Coetzee et al., 2006; Tia et al., 2006).  
 
The first case of pyrethroid resistance in A. gambiae s.l. was reported in Cote-d’Ivore and was 
attributed to the domestic use of aerosols. Pyrethroid resistance was reported in Kenya and 
was attributed to the use of permethrin-impregnated bed nets (Chandre et al., 1999), although 
impregnated bed nets were also used in the Gambia, pyrethroid susceptibility in A. gambiae 
s.s. did not change (Hemingway et al., 1995). More recently, A. gambiae and A. arabiensis 
were found to be resistant to pyrethroids (deltamethrin and lambda-cyhalothrin) and 
carbamates (propoxur) but not to organochlorines (DDT) in Mozambique (Casamiro et al., 
2006). In Burkina Faso and Benin, A. gambiae was resistant to both pyrethroids and DDT. 
Resistance was severe in Cote d’Ivore as A. gambiae mortality was as low as 7.1% with DDT, 
7.3% with permethrin and 28.4% with deltamethrin (Chandre et al., 1999). Resistance to DDT 
has also been reported in several South American countries, and in Mexico, India and in Sri 
Lanka (Davidson, 1963; Georghiou and Lagunes-Tejeda, 1991; Hemingway et al., 1997; 




1.6.2 Parasite resistance to antimalarials  
Antimalarial drug resistance is defined as the ability of the parasite strain to survive and/or 
multiply despite the proper administration and absorption of an antimalarial drug in the dose 
normally recommended. The development of drug resistance can be considered in two parts; 
the initial spontaneous genetic event which produces the resistant mutant and the subsequent 
selection process where the resistant mutants have a survival advantage in the presence of the 
drug and are the ones transmitted (WHO, 2006b). Antimalarial drug resistance has emerged as 
one of the greatest challenges facing malaria control today and has been implicated in the 
spread of malaria to new areas and re-emergence in areas where the disease had been 
eradicated. Drug resistance has also played a significant role in the occurrence and severity of 
epidemics in some parts of the world (Bloland, 2001). Figure 1.2 shows molecular structures 
of different antimalarials, for which resistance is discussed.  
 
1.6.2.1 Chloroquine Resistance 
Chloroquine (CQ) is a 4-aminoquinoline that is thought to interfere with the parasite’s haem 
detoxification pathway (White, 1999). CQ acts as a schizontocide by preventing the 
development of blood-stage malaria parasites. It is believed that CQ acts by binding to haem 
molecules in the parasite food-vacuole, which is a by-product of the parasite’s digestion of 
haemoglobin (Mita et al., 2009). Heam can be degraded by glutathione when it exits the food 
vacuole, however, the ability of CQ to inhibit this glutathione mediated degradation enables 
the cytotoxic activity of this antimalarial (Ginsburg et al., 1998). Resistance to CQ in P. 
falciparum may be multigenic and is initially conferred by mutations in the gene that codes for 
the P. falciparum chloroquine resistance transporter (pfcrt) gene, this leads to the reduction in 
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Figure 1.2: The molecular stuctures of antimalarials which are possible combination 
partners to artemisinins. Adapted from WHO 2006b. Guidelines for the treatment of 
malaria. Geneva, Switzerland.  
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Point mutations in the P. falciparum multidrug resistance 1 (pfmdr 1) gene are also associated 
with CQ resistance, though to a lesser extent (Ochong et al., 2003).  The first reports of CQ 
resistance occurred on the Thai-Cambodian border and in Columbia in the late 1950s, around 
12 years after the drug’s introduction. All endemic areas of South America were affected by 
1980 and almost all Asia and Oceania by 1989.  
 
In Africa, CQ resistance emerged in the east in 1978, spread to the central and southern parts 
of the continent before arriving in West Africa in 1983. By 1989, CQ resistance was 
widespread in sub-Saharan Africa (Wongsrichanalai et al., 2002). CQ resistance is less severe 
in west and central Africa than in east Africa, even in the west, its intensity varies from an 
advanced stage with severe effects on morbidity and mortality in focal areas of Senegal 
(Haruki et al., 1998; Trape, 2001) to a moderate level in Ghana (Landgraf et al., 1994) and 
Cameroon (Ringwald et al., 2000), and a low level in Mali (Djimde et al., 2001). The level of 
clinical failure after chloroquine treatment was estimated to be 44% in Madagascar (Menard et 
al., 2008). 
 
1.6.2.2 Amodiaquine resistance 
Amodiaquine (AQ) is a Mannich base 4-aminoquinoline with a mode of action similar to that 
of chloroquine. Although these two drugs are chemically related, AQ remains effective in 
areas of substantial CQ resistance (Van Dillen et al., 1999; Brasseur et al., 1999; Staedke et 
al., 2001). Cross resistance between CQ and AQ has been shown in some clinical and in vitro 
reports (Childs et al., 1989; Basco and Le Bras, 1993; Bloland and Reubush, 1996; White, 
1996; Schellenberg et al., 2002) but the molecular mechanism of that cross resistance is not 
fully understood. Mutations in two genes that code for CQ resistance, the pfcrt and the pfmdr1 
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genes have been identified in AQ resistant isolates in southern Sudan (Ochong et al., 2003). 
Treatment failure rates of 18% have been observed in the Democratic Republic of Congo 
(Bonnet et al., 2009). 
 
1.6.2.3 Sulfadoxine-Pyrimethamine Resistance 
Sulfadoxine and pyrimethamine (SP) act synergistically, the former inhibits dihydropteroate 
synthetase (DHPS) and the latter inhibits dihydrofolate reductase (DHFR). These two enzymes 
are involved in folate synthesis. Point mutations in the dhps and dhfr genes are implicated to 
confer resistance by decreasing the drug-binding affinity of the enzyme (Wongrischanalai et 
al., 2002). Although the precise relation between mutations in the dhps and dfhr genes in 
clinical SP resistance is unclear, Sibley et al. (2001) showed that the presence of a sensitive 
dhfr allele is highly predictive of SP treatment success irrespective of the dhps allele.  
Resistance to SP was first noted on the Thai-Cambodian border in the mid 1960s (Bjorkman 
and Phillips-Howard, 1990) and it became an operational problem in the same area within a 
few years of its introduction to the malaria control programme in 1975. High level resistance 
is found in South East Asia, southern China and the Amazon Basin. Lower degrees and 
frequencies of resistance are observed on the Pacific coast of South America, southern Asia 
east of Iran and western Oceania (Wongrischanalai et al., 2002).  
 
In Africa, SP sensitivity started declining in the 1980s and started gaining ground more in the 
east than in the west. Low sensitivity to SP was observed in Kenya and in Tanzania from the 
late 1980s to the early 1990s, pyrimethamine resistant isolates were present in the 1980s even 
before SP was widely used (Ronn et al., 1996; Mberu et al., 2000). In-vitro SP resistance has 
long been documented in sub-Saharan Africa; in varying prevalence from 13-30%, in 
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Tanzania (Alin, 1997), Equatorial Guinea (Benito et al., 1995), Gabon (Philips et al., 1998) 
and Ghana (Landgraf et al., 1994). Clinical failure rates of more than 25% have already been 
reported in Liberia (Checchi et al., 2002), Guinea Bissau (Kofoed et al., 2002) and Malawi 
(Plowe et al., 2004). KwaZulu-Natal, South Africa has also observed treatment failure rates of 
almost 90% following treatment with SP (Bredenkamp et al., 2001). The risk of treatment 
failure of 51-79% has also been observed in Uganda (Nankabirwa et al., 2010). 
 
1.6.2.4 Quinine resistance 
Quinine (Q) is an alkaloid derived from the bark of the Cinchona tree, it acts principally on the 
mature trophozoite stage parasites and does not prevent sequestration or further development 
of circulating ring-stage parasites (Krugliak and Ginsburg, 1991; Bray et al., 1991). Quinine 
also does not kill pre-erythrocytic stages of malaria parasites and has no gametocidal effect. 
The rates of treatment failure greater that 10% at 28 days following quinine treatment have 
been shown in Sudan (Kofoed et al., 2007) and in Thailand (Pukrittayakamee et al., 2000). 
The mechanisms of quinine antimalarial activity are thought to involve the inhibition of 
parasite heam detoxification in the food vacuole (Krugliak and Ginsburg, 1991; Bray et al., 
1991; WHO, 2006b).  
 
Observations of clinical resistance to quinine began to accumulate during the mid 1960s, 
especially from the Thai-Cambodian border. Now it occurs sporadically in South East Asia 
and Western Oceania (Wernsdorfer and Payne, 2001). Resistance is less frequent in South 
America (Zalis et al., 1998) and Africa (Jelinek et al., 2001). Wide-spread use of quinine in 
Thailand in the early 1980s as an interim therapy in the face of declining SP efficacy resulted 
in significant reduction in parasite sensitivity (Wongsrichanalai et al., 2002). There is some 
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suggestion that pfmdr1 mutations associated with chloroquine resistance may also account for 
reduced susceptibility to quinine (Wongsrichanalai et al., 2002). In a Brazilian study of 
pfmdr1 mutations, chloroquine resistant strains were found to have low susceptibility to 
quinine (Zalis et al., 1998). In the Gambia, pfmdr1 Tyr86 was weakly associated with 
decreased sensitivity to the drug (Duraisingh et al., 2000).  
 
1.6.2.5 Mefloquine resistance 
Mefloquine (MQ) is a 4-methanoquinoline and is related to quinine. Resistance to MQ was 
first observed near the Thai-Cambodian and the Thai-Myanmar borders in the late 1980s and 
its monotherapy is no longer effective there (Wongsrichanalai et al., 2002). There are also 
case reports of mefloquine resistance from the Amazon basin but the scope and degree of 
resistance in South America are still far below those of South East Asia. Though some in-vitro 
studies suggested the presence of P. falciparum strains with low MQ sensitivity in Africa, 
clinical resistance is rare (Wongsrichanalai et al., 2002). 
 
Copy number and polymorphisms of the P. falciparum multidrug resistance 1 gene (pfmdr1 
gene) have been investigated as molecular markers of MQ resistance; the evidence on 
increased pfmdr1 copy number as a molecular marker for MQ resistance remains conflicting. 
Some studies in Thailand suggested that a higher copy number confers MQ resistance (Price et 
al., 1999; 2004; Wilson et al., 1993) but other studies did not confirm that finding in Thailand 
(Chaiyaroj et al., 1999), Brazil (Zalis et al., 1998) and Africa (Basco et al., 1995). Some 
studies have shown increased sensitivity to mefloquine with the pfmdr1 Tyr86 mutation in the 
Gambia (Durraisingh et al., 2000) and in Thailand (Price et al., 1999), suggesting a possible 
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inverse relation between sensitivity to MQ and to CQ. Sowunmi and colleagues (2009a) 
observed 11% resistance at day 42, after treatment with mefloquine monotherapy.  
 
1.7 Alternative treatment for malaria 
Due to an increasing level of resistance of malaria parasites to non-artemisinin antimalarials, 
new therapeutic approaches have been developed, these include the use of artemisinin-based 
combination therapy (ACT). In this approach, an artemisinin drug is combined with a non-
artemisinin antimalarial to improve efficacy. The concept of combination therapy is based on 
synergistic or additive potential of two or more drugs with different mechanisms to improve 
therapeutic efficacy and to decrease drug resistance. This approach is well known to the 
treatment of bacterial and viral infections as well (Nosten and White, 2007). 
 
1.7.1 Artemisinin and its derivatives 
Artemisinin, also known as qinghaosu, is a sesquiterprene lactone extracted from the leaves of 
Artemisia annua (sweet wormwood). It was isolated by Chinese scientists in 1972. The plant 
has been used in China for the treatment of fever for over a thousand years (QARCG, 1979; 
WHO, 2006b; McIntosh and Olliaro, 1999). Artemisinins are potent and rapidly acting blood 
schizontocides, active against all Plasmodium species. They have an unusually broad activity 
against asexual parasites, killing erythrocytic stages from young rings to schizonts (Nosten 
and White, 2007). Artemisinins have a unique mode of action; they are well tolerated and have 
a gametocidal effect (Davis et al., 2005). Peak plasma concentrations occur around 3 hours 
following oral administration (WHO, 2006b).  
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When artemisinins are used alone over short periods (less than five days), clearance of 
parasites from the blood is only temporary (Meshnick, 1996; McIntosh and Olliaro, 1999) and 
they have a high rate of re-infections and recrudescences, although recrudescences occur less 
frequently (Yeka et al., 2005), hence they should be combined with other antimalarials to 
achieve maximum efficacy. Only four compounds of artemisinin have reached pharmaceutical 
development for use in humans; artesunate (AS), artemether (AM), dihydroartemisinin (DHA) 






Figure 1.3: The molecular structures of artemisinin and artemisinin derivatives. Artemisinin (a), 






Artesunate is one of the most commonly used artemisinin derivatives and can be given orally, 
rectally, intramuscularly or intravenously (WHO, 2006b). Artesunate is rapidly absorbed, with 
peak plasma levels occurring 1.5 hours after oral administration (Batty et al., 1998). It is 
almost entirely converted to dihydroartemisinin, the active metabolite (Navaratnam et al., 
2000). Elimination of artesunate is very rapid and the duration of its antimalarial activity is 
determined by the eliminination of dihydroartemisinin (half-life approximately 45 min) (Hien 
et al., 2004).  
 
1.7.1.2 Artemether 
Artemether (AM) is the methyl ether of dihydroartemisinin. It is more lipid soluble than 
artemisinin or artesunate. It can be given as an oil-based intramuscular injection or orally. It is 
also co-formulated with lumefantrine (previously referred to as benflumetol) for combination 
therapy. Peak plasma concentrations occur around 2–3 hours after oral administration. 
Artemether is metabolized to dihydroartemisinin and its elimination half life is approximately 
one hour (Ezzet et al., 1998). 
 
1.7.1.3 Dihydroartemisin 
Dihydroartemisinin is the main active metabolite of the artemisinin derivatives, but can also be 
given orally and rectally as a drug in its own right. It is relatively insoluble in water and 
requires formulation with suitable excipients to ensure adequate absorption. It achieves cure 
rates similar to those of oral artesunate. Dihydroartemisinin is rapidly absorbed following oral 
administration, reaching peak levels after around 2.5 hours. Its elimination half-life is 
approximately 45 minutes via intestinal and hepatic glucuronidation (Newton et al., 2002). 
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1.7.1.3 Arteether 
Arteether, more recently known as artemotil, is the ethyl ether of artemisinin. It is closely 
related to the more widely used artemether. It is oil-based, water-insoluble and is given by 
intramuscular injection only. Absorption of artemotil is slower, with some patients having 
undetectable plasma artemotil until more than 24 hours after administration (WHO, 2006b) 
 
1.7.2 Artemisinin-based combination therapy for the treatment of malaria 
Although there are some minor differences in oral absorption and bioavailability between the 
different artemisinin derivatives used for the oral treatment of uncomplicated malaria, there is 
no evidence of significant clinical differences in current formulations (WHO 2006b). The 
properties of a partner antimalarial are crucial and they determine the efficacy and choice of a 
combination therapy. The ACTs combine a derivative of the natural product of artemisinin 
with longer lasting partner drug that continues to reduce the parasite biomass after the short-
lived artemisinin has dropped below therapeutic levels (Greenwood et al., 2008). Currently 
recommended ACTs are artemether-lumefantrine, dihydroartemisinin-piperaquine, artesunate 
plus amodiaquine, artesunate plus mefloquine and artesunate plus sulfadoxine-pyrimethamine. 
Artemether-lumefantrine was the first internationally recognized fixed-dose ACT in use but 
other fixed-dose combinations have later been developed (Nosten and White, 2007). 
Dihydroartemisinin-piperaquine has also been investigated and it is part of the WHO 
recommendations published (Sinclair et al., 2009; WHO, 2010). 
 
1.7.2.1 Artemether-lumefantrine  
Artemether-lumefantrine (AL) is currently available as co-formulated tablets known as 
CoartemTM or RiatemTM, it was previously recommended as a four-dose regimen (AL-4) but 
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now it is currently recommended at six-doses (AL-6), two doses a day for three days. Its 
advantage is that lumefantrine, previously referred to as benflumetol, is not available as a 
monotherapy and has never been used on its own. This has limited the potential of 
lumefantrine-resistant parasites (WHO, 2006b). A systematic review (Omari et al., 2004) 
reported a higher risk of treatment failure at days 28 and 63 with AL-4 compared to the 
combination of artesunate plus mefloquine (AS+MQ). There was no statistically significant 
difference in the risk of treatment failure at day 28 when AL-6 was compared to AS+MQ. On 
day 42, there was a significantly higher risk of treatment failure with AL-6 compared to 
AS+MQ. Compared to artesunate plus amodiaquine (AS+AQ), there was a significantly lower 
risk of treatment failure at day 28 in AL-6. The risk of parasitological failure was not 
significantly different when AL-6 was compared to dihydroartemisinin+napthoquine+ 
trimethroprim (Omari et al., 2005; Burkiwa et al., 2006). 
 
The disadvantage of using AL is that it requires a complicated twice daily dose and has to be 
administered with milk or fat-containing foods. This could potentially be a problem in poor 
households, considering that the most malarious areas are also poverty stricken (Muheki et al., 
2004; Kobbe et al., 2008).  
 
1.7.2.2 Artesunate plus amodiaquine, mefloquine or sulfadoxine-pyrimethamine 
Artesunate plus amodiaquine (AS+AQ) is currently available in blister packs as separate 
scored tablets containing 50mg of artesunate and 153 mg base of amodiaquine. Its co-
formulation has recently been developed and the treatment is recommended for three days 
(Nosten and White, 2007). The combination is sufficiently efficacious only where 28-day cure 
rates with AQ monotherapy exceed 80% (WHO, 2006b). With the potential for cross 
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resistance with CQ, and the availability of both AQ and CQ as monotherapies, the efficacy of 
this ACT may be compromised. The co-formulated dose of artesunate plus mefloquine 
(AS+MQ) has been developed and the treatment is recommended for three days (Ashley et al., 
2006). Artesunate plus sulfadoxine-pyrimethamine (AS+SP) is also currently available as 
separate scored tablets. High level of resistance to SP, the continued use of SP for intermittent 
preventive treatment of malaria in pregnancy, the wide spread availability of SP, sulfalene-
pyrimethamine and cotrimoxazole (trimethoprim-sulfamethoxazole) are likely to compromise 
the efficacy of combination therapy using SP (WHO 2006b).  
 
1.7.2.3 Dihydroartemisinin-piperaquine 
The other promising form of ACT is Dihydroartemisinin-piperaquine (DHAP). It is well 
tolerated and has no significant cardio-vascular or metabolic side effects (Davis et al., 2005). 
This ACT which has been co-formulated as ArtekinTM has been shown to be safe and 
effective, and represents another option for malaria treatment (Sinclair et al., 2009). 
Piperaquine is a bisaminoquinoline synthesized in China and France in the 1960s (Chen et al., 
1982), frequently used in China in the 1970s and 1980s and was re-discovered in the 1990s as 
a candidate for ACT (Davis et al., 2005). Although the long half-life of piperaquine (3-4 
weeks) may allow resistant parasites to be selected, this has not been of concern in areas of 
Thailand where transmission is low (Davis et al., 2005). The cost of using ArtekinTM is lower 
than that of using CoartemTM 
 
so it could be an attractive option (Denis et al., 2002).  
1.7.3 Other potential artemisinin based combinations 
The partner drug to artemisinins should be well tolerated and nontoxic, it should be present in 
the blood at therapeutic concentrations for at least several times the duration of the parasite 
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life cycle, which is 48 hours in the case of P. falciparum (Davis et al., 2005). Primaquine 
which also has a gametocidal effect against P. falciparum reaches peak plasma concentration 
around 1-2 hours after administration and has an elimination half-life of 3-6 hours (Mihaly et 
al., 1984) and is effective even against stage five gametocytes (Pukrittayakamee et al., 2004). 
Similar to lumefantrine, atovaquone needs to be administered with fat-containing foods due to 
poor absorption (McGrey et al., 2003). It is available in co-formulation with proguanil. 
Proguanil on the other hand is poorly metabolized by approximately 3% of the African 
population (Helsby et al., 1990; Kaneko et al., 1999). The elimination half-life of proguanil 
and its active metabolite, cycloguanil is approximately 20 hours (Wattanagoon et al., 1987; 
Hussein et al., 1996). Chlorproguanil has similar properties to proguanil and is co-formulated 
with dapsone as LapdapTM
 
. Peak plasma concentrations of dapsone occur 2-8 hours after an 
oral dose, its elimination half-life is 10-50 hours (WHO, 2006b). Chlorproguanil-dapsone has 
been withdrawn due to safety concerns (Burkiwa et al., 2004). 
Tetracyclines are a group of antibiotics originally derived from certain Streptomyces species, 
but mostly used in synthetic form. Tetracycline itself is water soluble and an inhibitor of 
aminoacyl-tRNA binding during protein synthesis. The target for tetracyclines is the 
apicoplast, a chloroplast-like organelle with uncertain functions. Tetracyclines cause modest 
antimalarial effects initially but are much more potent against the progeny of treated parasites. 
Blocking production of apicoplast proteins causes the delayed death effect. Although too slow 
acting to be used as monotherapy, antibiotics targeting apicoplast functions could be ideal 
partners for combination therapy with artemisinins (Dahl and Rosenthal, 2008). 
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Peak plasma concentrations occur 1-3 hours after ingestion and its elimination half-life is 
around eight hours. Administration with antacids, iron preparations and dairy products should 
be avoided. Doxycycline, which is also a tetracycline, has a longer half-life (10-24 hours) 
(Newton et al., 2005) and is better absorbed. It should not be given to pregnant or lactating 
women or children aged up to eight years. Doxycycline has a lower binding affinity with 
calcium so it can be taken with food or milk. Clindamycin is very soluble in water and it 
inhibits the early stages of protein synthesis. Peak plasma concentrations are reached in one 
hour in children and three hours in adults. Its elimination half-life is 2-3 hours (WHO, 2006b). 
 
Other combinations with artemisinins include combination with methylene blue (MB), 
Cotrimoxazole (CT), Sulfamethoxy-pyrimethamine (SMP), atovaquone-proguanil 
(ATV+PRG), β-cyclodextrin (β-CDX) and others. Methylene is a specific inhibitor of P. 
falciparum glutathione reductase; it inhibits the heme polymerization within the parasite’s 
food vacuole and prevents methaemoglobinaemia in clinical malaria (Zoungrana et al., 2008). 
Cotrimoxazole, a combination of sulfamethoxazole and trimethoprim, has an antimicrobial 
spectrum that includes bacterial infections and protozoan infections such as malaria. 
Compared with sulfadoxine-pyrimethamine, CT supports less gametocyte generation. 
Cotrimoxazole and AS are often used together and are both easily available (Fehintola et al., 
2008). A long-acting sulfonamide, SMP, has a long but stable elimination half-life of 
approximately 80 hours and its low plasma-binding capacity (65%) enables use of a low 
dosage with a long-lasting effect on parasites (Rulisa et al., 2007).  
β-cyclodextrin has been shown to improve the absorption of artesunate (Wong et al., 2003). 
Atovaquone-proguanil is very well tolerated and effective against multidrug-resistant P. 
falciparum isolates (Van Vugt et al., 2002). When atovaquone was used alone, high level 
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resistance was selected rapidly. The addition of proguanil reduced this considerably, but 
because proguanil is a relatively weak antimalarial drug, the degree of protection against 
resistance may not be sufficient to prevent the development of resistance to the combination if 
it is used widely (Van Vugt et al., 2002). 
 
1.7.4 Resistance to ACTs 
Although artemisinins are effective and rapidly acting, their widespread use has raised 
questions with regards to emerging drug resistance (Duffy and Sibley, 2005). In-vitro drug 
susceptibility data as well as reports of failurerates associated with ACTs suggest the 
possibility of clinical artemisinin resistance. In the Thai-Cambodian border, an artesunate-
mefloquine 28-day cure rate of 78.6%-85.7% has been observed (Vijaykadga et al., 2006; 
Mey Bouth et al., 2006). These studies suggest declining susceptibility to this ACT. However, 
it is not yet clear whether these failures are a result of true parasite resistance or not (Alker et 
al., 2007). Dondorp et al. (2009) observed 30% PCR confirmed recrudescence in Pailin, 
Cambodia after 21-35 days of treatment with artesunate monotherapy, which could not be 
explained by pharmacokinetic or other host factors. There was also no consistant pattern of 
genetic mutations in this study, despite clear evidence of in-vivo artesunate resistance.  
Although there has been some decline in the efficacy of ACTs, the relative contributions of 
resistance to artemisinins, the partner drug and other factors have not been clarified (Dondorp 






1.8 Rationale for the study 
The World Health Organization has endorsed ACT as the 1st
 
-line treatment for uncomplicated 
Plasmodium falciparum malaria (Davis et al., 2005) and many countries are changing their 
treatment policies in that regard. By June 2006, 39 African countries had changed their 
policies to recommend ACTs as the first line treatment for uncomplicated malaria, to reduce 
the effects of failing monotherapies and to limit the development of drug resistance (Zurovac 
et al., 2007).  South African treatment guidelines have also adopted ACTs for the treatment of 
uncomplicated malaria and artemether-lumefantrine is the treatment of choice (Olumese, 
2006). Several clinical trials have proven the superior efficacy of ACTs compared to non-
artemisinin based regimens (McIntosh and Olliaro, 1999). Reviewing different ACTs, there is 
no consensus on which antimalarial is better suited for combination with the various 
artemisinin derivatives. In a Cochrane review, DHAP was equivalent to AL, ASMQ, ASAQ 
and ASSP in reducing the risk of treatment failure. In the same review, AL was also 
equivalent to ASMQ and ASAQ, however, it was superior to ASSP (Sinclair et al., 2009). The 
above review evaluated ACTs compared to each other; however, the ACTs have not been 
evaluated when the same artemisinin derivative is combined with different non-artemisinin 
drugs, thus only evaluating the non-artemisinin partner of the combination therapy.  
The aim of this study was to review the evidence of efficacy and safety of different non-
artemisinin antimalarials when they are combined with the same artemisinin derivative, in 
reducing the risk of treatment failure in non-pregnant adults and children with uncomplicated 
P. falciparum malaria.  
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Included trials were randomized controlled trails in non-pregnant adults and children with 
uncomplicated P. falciparum malaria, evaluating the efficacy and safety of non-artemisinin 
antimalarials like amodiaquine, mefloquine, chloroquine and others, combined with 
artemisinin, artesunate, artemether or dihydroartemisinin in reducing the risk of treatment 
failure. The intervention was compared with a different non-artemisinin antimalarial in 
combination with the same artemisinin derivative given in the intervention arm, or 
monotherapy of the same artemisinin derivative without the non-artemisinin antimalarial. 
 
Objectives 
• To systematically review the evidence of the efficacy and safety of different non-
artemisinin antimalarials when combined with the same artemisinin derivative for the 














CHAPTER 2: METHODS 
 
2.1 Criteria for including studies in the review 
2.1.1 Types of studies 
This review considered only randomized controlled trials (RCTs), quasi-randomized 
controlled trials (CCT) were excluded. 
 
2.1.2 Participants 
The participants were non-pregnant adults and children with uncomplicated Plasmodium 
falciparum malaria, confirmed by a blood slide using thick smears. The focus of this study 
was uncomplicated malaria, particularly because the vast majority of malaria infections cause 
uncomplicated disease with approximately 1-2% of these episodes becoming severe. Pregnant 
women were excluded as artemisinins are not recommended for women in their first trimester 
of pregnancy due to limited safety data (WHO 2006b). 
 
2.1.3 Interventions 
The interventions were non-artemisinin antimalarials like amodiaquine, mefloquine, 




The interventions were compared with a different non-artemisinin antimalarial in combination 
with the same artemisinin derivative given in the intervention arm, or monotherapy of the 
same artemisinin derivative without the non-artemisinin antimalarial. Since the aim of this 
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review was to compare different non-artemisinin antimalarials combined with the same 
artemisinin derivative, RCTs that compare two different artemisinin derivatives combined 
with the same or two different non-artemisinin antimalarials were excluded, for example, 
artemether-lumefantrine was not compared with artesunate-amodiaquine, since the artemisinin 
derivatives are different in a single trial, irrespective of the difference in the combination non-
artemisinin antimalarial.  
 
2.1.5 Outcomes 
The definitions of treatment failure used in this review were first drawn from the WHO 2006 
treatment guidelines (WHO, 2006), then combined to be consistent with the WHO 2010 
treatment guidelines (WHO, 2010) and a Cochrane review by Sinclair et al., (2009). The 
primary outcome was treatment failure adjusted by polymerase chain reaction (PCR), refered 
to as adjusted treatment failure, which includes early treatment failure or late parasitological or 
clinical failure on or before day 28. In late treatment failure, new infections and 
recrudescences were differentiated by PCR where data was provided. When PCR was not used 
and it was not possible to clarify whether failure was a result of new infections or 
recrudescence, treatment failure was presented as unadjusted treatment failure.   
• Early treatment failure (ETF) defined as danger signs or complicated malaria or failure to 
adequately respond to therapy on days 0–3 
• Late clinical failure (LCF) defined as danger signs or complicated malaria or fever and 
parasitaemia on days 4–28 without previously meeting criteria for ETF,  
• Late parasitological failure (LPF) defined as asymptomatic parasitaemia day 28 without 
previously meeting criteria for ETF or LCF 
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• Late treatment failure defined as failure to respond to treatment between day 4 and day 
28 not categorized as clinical or parasitological.   
 
Secondary outcomes were: 
• Fever clearance time defined as the time between starting treatment and the temperature 
returning back to normal and remaining normal for more that 48 hours. 
• Fever on day two 
• Fever on day three 
• Parasite clearance time (PCT) defined as the time between starting treatment and the first 
negative blood test, if negativity persists for more than 48 hours. 
• PCT 50 defined as the time it takes for the parasites to be reduced to 50% of the first 
value 
• PCT 90 defined as the time it takes for the parasites to be reduced to 10% of the first 
value 
• Anaemia on day 28 defined as hemoglobin level 
• Gametocyte carriage on days seven, 14 and 28 
< 11 g/dL (Kayentao et al., 2009) 
Adverse events leading to discontinuation of treatment, hospitalization and death were noted 
as well as side effects not leading to discontinuation of treatment as defined by trial authors.  
 
2.2 Search strategy for the identification of studies for inclusion in the review 
The search for studies attempted to identify all relevant RCTs regardless of language or 
publication status. The first search was conducted in June 2007 and the last one in January 
2009. Only RCTs that were published and indexed before the end of January 2009 were 
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included. The search for published RCTs was conducted on the Cochrane Central Register of 
Controlled Trials (CENTRAL) (The Cochrane Library 2008, Issue 4), MEDLINE (1966-
January 2009) and EMBASE (1980-January 2009) using ‘malaria’, ‘artemisinin’, ‘artesunate’, 
‘artemether’ and ‘dihydroartemisinin’ as search terms. The detailed search strategies are 
included in Appendix A. Ongoing RCTs were searched for from the trials registry; 
ClinicalTrials.gov (http://clinicaltrials.gov).  
 
Abstracts of conference proceedings were also searched from the following meetings:  
• Fifth European Congress on Tropical medicine and International Health, 24-28th
• Sixth European Congress on Tropical medicine and International Health, 6-10
 May 
2007, Amsterdam, The Netherlands. 
th 
• Fifth AMANET Biennial Conference, 26-28
Spetember 2009, Verona, Italy. 
th
• Gordon Research Conference on Malaria, 9-14
 February 2007, Zanzibar, Tanzania. 
th
• Gordon Research Conference on Malaria, 6-11
 September 2007, Oxford, United 
Kingdom. 
th
• Fourth Cost B22 Anual Congress, 10-13
 September, 2009 Magdalen College 
Oxford, United Kingdom 
th
• Malaria 2007, 21
 June 2007, Dundee. 
st-27th
• 4
 April 2007, The Gambia. 
th MIM Pan African Malaria Conference, 13-18th
• 5
 November 2005, Youde, Cameroon. 
th MIM Pan African Malaria Conference, 2nd-6th
 
 November 2009, Nairobi, Kenya. 
The reference lists of all RCTs identified by the above methods were checked. 
 42 
2.3 Methods for selecting studies for inclusion in the review 
The results of the search were scanned applying the eligibility criteria and the full articles of 
all potentially relevant studies were retrieved. Studies were scrutinized for possible multiple 
publications and assessed for inclusion in the review using standard eligibility forms based on 
the inclusion criteria. The eligibility form is included in Appendix B.1. Studies that did not 
meet the eligibility criteria were excluded. Authors of unpublished conference abstracts and 
those obtained from the trials registry were contacted for full data. If data was not successfully 
obtained or the trial was still ongoing, those RCTs were included as RCTs with no data 
extracted.  
 
2.4 Assessment of the methodological quality of included studies  
Each RCT’s methodological quality was assessed using standard methodological quality 
forms. The methods used to generate the sequence of allocating patients to different treatments 
and to conceal allocation sequence were classified as adequate, if the sequence could not be 
predicted, unclear, if the methods were not described or inadequate if the next allocation could 
be predicted using adopted guidelines (Juni, 2001). Blinding of participants, care givers or 
outcome assessors to the interventions in each trial was noted. Furthermore, the percentage of 
randomized participants excluded in the analysis was also noted and reported as loss to follow-
up. The methodological quality form is also included in Appendix B.2. 
 
2.5 Extraction of data from studies included in the review 
Data from included studies were extracted using standard data extraction forms (Appendix 
B.3). The following information was gathered from each included study:  
 43 
• Administrative details - Identification; author(s); publication status; year of publication; 
year in which study was conducted; details of other relevant papers cited. 
• Details of study - study design; inclusion and exclusion criteria; number of participants 
analyzed; type, duration, frequency and completeness of follow-up; country and location 
of the study; setting in which the study was performed (e.g. urban or rural), local malaria 
transmission and local drug resistance. Local malaria transmission and resistance to 
antimalarials were extracted as reported in the literature at the time the study was 
conducted or in a related study. 
• Characteristics of participants - age and sex. 
• Details of intervention - drugs administered, route of administration, duration of use, size 
and frequency of dose. 
• Details of outcomes - number of people experiencing a specific outcome. 
• Details of study ethics- independent ethics review board and type of informed consent. 
 
Authors of trials with insufficient or missing data were contacted for more information. For 
dichotomous outcome measures, the number of participants experiencing the event (n) and the 
number analyzed in each group (N) were recorded. For continuous outcome measures, means 
and standard deviations (SD) were extracted for each group together with the numbers 
analyzed in each group.  
 
2.6 Analysis of data extracted from studies included in the review 
Data were synthesized and analyzed using Review Manager 4.2 and 5.0. Dichotomous data 
were presented and combined using relative risks (RR). Continuous data were summarized by 
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means and standard deviations and combined using weighted mean differences (WMD). Both 
effect measures were accompanied by 95% confidence intervals (CI) and p-values. In cases 
where data were not normally distributed, thus means not reported, data were descriptively 
analyzed. Heterogeneity amongst trials was assessed by visually inspecting forest plots, 
applying the chi-squared test with a p-value of 0.1 indicating statistical significance and using 
the I2
 
 test (Higgins and Green, 2006) where a value of 75-100% was used to denote 
considerable heterogeneity. In cases where moderate heterogeneity was detected but it was 
still appropriate to combine the results, the random-effects model was used and potential 
sources of heterogeneity were explored and discussed (DerSimonian and Laird, 1986). In 
cases where the meta-analysis was not possible to conduct due to considerable heterogeneity, 
the results were only described. Differences in malaria transmission, local drug resistance and 
age groups of participants enrolled were investigated as potential sources of heterogeneity, and 
where considerable differences were found, subgroup analyses were performed. Due to 
inadequate reporting of the methods used in clinical trials, the sensitivity analysis for this 
review was not performed. The sensitivity analysis would have been conducted by subgroup 
analysis of RCTs according to the risk of bias and by imputing data on loss to follow up, either 








CHAPTER 3: RESULTS 
 
3.1 Description of the studies included in the review 
The search for literature provided 2354 abstracts and titles across the databases, 2245 were 
clearly described in the abstract and title, and did not meet the criteria for inclusion in the 
review and were, therefore, excluded. These studies were either clearly not Randomized 
Controlled Trials (RCTs), participants had severe malaria, had other forms of malaria not 
caused by Plasmodium falciparum or the interventions compared did not include the same 
artemisinin derivative in both arms, with only a differing combination antimalarial. The 
abstracts were re-screened two months from the initial screening to ensure that no abstracts or 
titles within the inclusion criteria were discarded. There were 109 potentially relevant studies 
that were identified. These abstracts were screened for duplicate studies identified in more 
than one database, thus excluding 43 studies. It was not clear if 66 remaining studies qualified 
for inclusion or not, thus full-text articles were sought and they were further evaluated for 
eligibility using a standard eligibility form. Eighteen of these were unpublished studies 
obtained from conference proceedings and clinical trials registries. Data and the description of 
methods for unpublished studies were sought from the investigators. There were 47 RCTs that 
met the inclusion criteria, one of them was in Spanish and interpretation for it was sought. 
Nineteen were excluded and the reasons for excluding them are shown in Table 3.1. Data for 
10 unpublished RCTs could not be obtained, the available data has been captured in Table 
3.2e, leaving 37 included and extracted RCTs. Figure 3.1 shows the flow diagram with 





Table 3.1: Characteristics of the studies that did not meet the eligibility criteria.  
Reference Reasons for exclusion 
Tall et al., 2005 Quasi-randomization 
Nahum et al., 2007 The trial compared ACT with a non-ACT antimalarial 
Osorio et al., 2007 The trial compared ACT with a non-ACT antimalarial 
Van den Broek et al., 2005 Quasi-randomization 
Price et al., 1999 The study was a review 
Krudsood et al., 2002 Quasi-randomization 
Sowunmi et al., 2001 Children had severe malaria 
Von Seidlein et al., 2003 The control group received placebo only 
Targett et al., 2001 The trial compared different AS doses with the same partner drug 
Looareesuwan et al., 1992b Study not a randomized controlled trial 
Sabchareon et al., 1998 The trial compared AS with AS suppository with the same partner drug 
Newton et al., 2001 Patients required intra-venous treatment (sign of severe malaria) 
Ibrahium et al., 2007 Not described as randomized  
Odhiambo, 2009 The trial was for prevention of malaria instead of treatment. 
Mworozi et al., 2009 The participants received different artemisinin derivatives with different 
combination antimalarials (Artemisinin vs Artemether) 
Tona et al., 2009 Intervention drug not identified 
Kabongo et al., 2009 Not a trial 
Maiga et al., 2009 The trial was for prevention of malaria instead of treatment. 







































Figure 3.1: Flow diagram showing the studies that were included or excluded in this review. 
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(n= 2354) 





Unpublished RCTs with no data, 
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The thirty-seven included RCTs had a total of 6862 analyzed participants, the number of 
participants ranged from 34 to 1066 in these trials. Tables 3.2 (a) to (e) show the details of 
included trials. 
 
3.1.1 Location, transmission intensity and drug resistance 
Twenty-one of the RCTs were conducted in Africa, one in each of Angola, Guinea, Guinea-
Bissau, Ghana, Mozambique, Rwanda, Senegal and Sudan (Tables 3.2a-e). There were two 
RCTs conducted in Burkina-Faso, in the Democratic Republic of Congo, Mali, Sudan and in 
Tanzania. Three RCTs were conducted in Nigeria. There were 14 RCTs conducted in Asia, 
nine in Thailand, three Vietnam, one in China and one in Malaysia. Only two trials were 
conducted in South America, in Colombia and in Ecuador. These trials were conducted in 
areas of varying malaria transmission. Twenty-two of them were conducted in endemic 
regions; three in areas with seasonal malaria transmission and eleven were conducted in areas 
of low to moderate transmission  (Tables 3.2a-e). Chloroquine and sulfadoxine-pyrimethamine 
resistance was reported in all the locations. Furthermore, multi-drug resistance was reported in 
Thailand, Vietnam and in Sudan. Resistance to amodiaquine was rare, reported only in the 
DRC (Van den Broek et al., 2006) while halofantine resistance was reported in Burkina Faso 
(Barennes et al., 2004; Zoungrana et al., 2007) and proguanil resistance reported in Malaysia 
(Wong et al., 2003). 
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LOCATION TRANSMISSION RESISTANCE AGE FOLLOW-UP  (days) 
Abacassamo et al., 2004 AS+SP 3 days Mozambique Seasonal CQ 6-59 months 14  
Bonnet et al., 2007 AS+SP 3 days
 
$ Guinea Seasonal CQ 6-59 months 28  
Carmona-Fonseca et al., 
2008 
AS+SP 3 days Colombia Low  CQ, SP, AQ 1 year and older 28 
Guthmann  et al., 2005 AS+SP 3 days 
 
Angola Hyper-endemic CQ, SP 6-59 months 28  
Hamour  et al., 2005 AS+SP 3 days Sudan Seasonally 
endemic 
MDR 6-59 months 28  
Kayentao  et al., 2009 AS+SP 3 days Mali Endemic CQ, SP 5-59 months 28  
        
Swarthout  et al., 2006 AS+SP 3 days DRC Endemic CQ, SP 6-59 months 28  
Van den Broek  et al., 2006 AS+SP 3 days DRC Highly endemic CQ, SP 6-59 months 28  




Mali Hyper-endemic CQ, SP 0.5-38 years 28 
Faye  et al., 2007 AS+MQ 3 days Senegal Moderate CQ Not reported  28  
Owusu-Agyei et al. 2008 AS+CD 3 days Ghana Endemic CQ, SP 0.5-10 years 28 
Zoungrana et al., 2008 AS+MB 3 days Burkina-Faso Endemic CQ, SP, 
Halofantrine 
0.5-10 years 28 
Fehintola et al., 2008 AS+CT 3 days Nigeria Endemic CQ, SP 0.5-10 years 28 
Barennes  et al., 2004 AS 3 days Burkina Faso Endemic  CQ, SP, 
Halofantrine 
1-15 years 28  
Sowunmi  et al., 2007 AS 7 days (both 
arms) 
Nigeria Endemic CQ, SP 0.5-11 years 21  
Sowunmi  et al., 2009 AS 3 and 7 days 
(monotherapy) 
Nigeria Endemic CQ, SP 0.5-11 years 42 
AS = artesunate, SP = sulfadoxine-pyrimethamine, MQ = mefloquine, CD = chlorproguanil-dapsone, MB = methylene-blue, CT= cotrimoxazole, CQ = 
chloroquine, MDR= multidrug resistance, DRC= Democratic Republic of Congo, $
 






Table 3.2 (b): Characteristics of studies that were included- artesunate plus mefloquine combination therapy. 
REFERENCE 
 CONTROL 
DURATION OF ARTEMISININ 
DOSES LOCATION TRANSMISSION RESISTANCE AGE 
FOLLOW-
UP (days) 
Gomez et al., 2003 AS In combination therapy- 3 days$$





Endemic CQ & MQ 1-12 
years 
28 
Karbwang et al., 1996 AS In combination therapy- single dose  
In monotherapy- 5days 
Thailand Low MDR 15-58 
years 
28 & 42 
Looareesuwan  et al., 1992 AS 5days 
 
Thailand Low MDR 16-60 
years 
28  
Price  et al., 1998 AS 5days  
 
Thailand Low MDR Not 
reported 
42  




Thailand Low MDR >14 
years 
28  
Li  et al., 1984 AS+MQ+SP 
AS 
 
In combination therapy-single dose 
In monotherapy- 3days 
China Low CQ & SP 8-60 
years 
28  
Van Vugt et al., 2002 AS+ATV+PRG 3 days Thailand Low MDR 2-70 
years 
42  
AS = artesunate, AZ = azithromycin, MQ = mefloquine, SP = sulfadoxine-pyrimethamine, ATV = atovaquone, PRG = proguanil, CQ = chloroquine,  
MDR = multidrug resistance, $$ 
 
















Table 3.2 (c): Characteristics of studies that were included- artemisinin derivatives in monotherapy. 
REFERENCE TREATMENTS DURATION OF 
ARTEMISININ DOSES 
LOCATION TRANSMISSION RESISTANCE AGE  (years) 
FOLLOW-UP 
 (days) 
Hassan Alin et al., 1996 A+MQ vs A In combination therapy-3 days 
In monotherapy- 5days 
Tanzania Holo-endemic CQ & SP 15-45  28  
Karbwang  et al., 1995 AM+MQ vs AM In combination therapy- 1day  
In monotherapy- 5 
Thailand Low MDR 13-47  28 & 42 * 
Looareesuwan  et al., 1997 AM+MQ vs AM In combination therapy- 1day  
In monotherapy- 5 or 7days  
Thailand Low MDR 16-60  28  




Thailand Low MDR >14  28  
Li  et al., 1984 AS+MQ+SP vs AS 
 
In combination therapy- single dose 
In monotherapy-  3days 
China Low CQ & SP 8-60  28  
Kofoed  et al., 2003 AS+CQ vs AS 3days  
 
Guinea-Bissau Seasonal CQ 0.5-15.5  35  
Pukrittayamee  et al., 2004 AS+PQ vs AS 7days  Thailand Low MDR 14-62  28  
Wong  et al., 2003 
 
A+β-CDX vs A 5days oral  
 
Malaysia Endemic CQ, SP & PRG 15-61  35  
Diem Thuy et al., 2007 DHA+MQ vs DHA 5 days in monotherapy  
2 days in combination therapy 
Vietnam Endemic MDR ≥15  28 & 42* 
 
A = artemisinin, AM = artemether, AS = artesunate, MQ = mefloquine, AZ = azithromycin, CQ = chloroquine, PQ = primaquine, β-CDX = beta-cyclodextrin, 
















Table 3.2 (d): Characteristics of the studies that were included - other combination therapies. 
REFERENCE TREATMENTS DURATION OF ARTEMISININ DOSES LOCATION TRANSMISSION RESISTANCE AGE 
FOLLOW-
UP (days) 
Huong et al., 2003 
 
AS+SP vs AS+CQ 3days 
 
Vietnam Highly endemic CQ & SP 4-65 years 28  
Rulisa et al 2007 
 
AS+SP vs AS+SMP 3 days Rwanda Endemic CQ & SP 3 months -
12 years 
28 
Shekalaghe et al., 2007 AS+SP vs 
AS+SP+PQ 
3 days Tanzania Hyper-endemic CQ & SP 3-15 years 42 
Bich et al., 1996 A+Q vs A+D single dose 
 
Vietnam Hyper- and Holo-
endemic 
MDR 8-65 years  28  
Na-Bangchang et al., 1996 AM+D vs AM+AZ In AM+D- 5days.  
In AM+AZ- single dose 
Thailand Low MDR 15-59 years 28  
AS = artesunate, A = artemisinin, AM = artemether, CQ = chloroquine, SP = sulfadoxine-pyrimethamine, Q = quinine, D = doxycycline, AZ = azithromycin,  



















Table 3.2e. Characteristics of unpublished included studies. 
 
 







REFERENCE TREATMENTS DURATION  LOCATION TRANSMISSION RESISTANCE AGE FOLLOW-UP 
Newman, unpublished AS+AQ vs AS+SP 3 days Mali Hyperendemic CQ, SP 6-59 months 28 days 
Lameyre,  unpublished AS+AQ vs AS+SP 3 days Mali Endemic CQ, SP ≥6 months 28  days 
Graham,  unpublished AS+AQ vs AS+SP vs 
AS+CQ 
3 days Parkistan Endemic CQ, SP 5-70 years 28 days 
D’Alesandro,  unpublished AS+AQ vs AS+CD 3 days Multinational Differs  Differs  6-59  months 63 days 
Bronzan, unpublished (a) AS+AQ vs AS+CD 3 days Malawi Endemic CQ, SP 6-59 months 28 days 
Bonzan,  unpublished (b) AS+AQ vs AS+CD 3 days Malawi Endemic CQ, SP ≥5 years 28 days 
Mueller,  unpublished AS+AQ vs AS+MB 3 days Burkina Faso Endemic CQ, SP 6-59 months 28 days 
Borghini-Fuhrer,  unpublished AS+MQ vs AS+PR 3 days Multinational Differs Differs  3-60 years 28 days 
Fofana, unpublished AS+AQ vs AS+SP 3 days Mali Endemic CQ, SP Unclear 28 days 
Rueangweerayut, unpublished AS+MQ vs AS+PR 3 days South East Asia 
and Africa 
Differs CQ, SP Unclear  28 days 
Dembele, unpublished (a) AS+AQ vs AS+SP 3 days Mali Endemic CQ, SP Unclear 28 days 
Dembele, unpublished (b) AS+AQ vs AS+SP 3 days Mali Endemic CQ, SP Unclear 28 days 
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3.1.2 Participants included 
Participants in these trials were male and female participants, in 11 trials only children aged 
between 6 and 59 months were included, one trial included children from the age of three 
months (Rulisa et al., 2007). Twenty-two RCTs included adults and in one, up to 70 years old 
(Tables 3.2a-d). All the participants included in these RCTs were febrile or had a history of 
fever in the previous 24 hours. They were also included if they had parasitaemia of 1000 or 
2000 up to 100 000 or 200 000 parasites/μL. Pregnancy, mixed plasmodium infection, severe 
malaria and other concomitant febrile or severe illnesses were exclusion criteria common in all 
trials.  
 
3.1.3 Interventions investigated 
Four trials had three intervention arms relevant for this review (Djimde et al., 2008; Krudsood 
et al., 2000; Li et al., 1984; Graham, unpublished), these were split into three comparisons and 
the rest of the trials had only two intervention arms relevant in this review. In 14 trials, there 
were intervention arms where participants were given non-artemisinin treatments, or 
artemisinins not relevant to the objectives of this review and data on these participants were 
not extracted (Fehintola et al., 2008; Guthmann et al., 2005; Van den broek et al., 2006; 
Abacassamo et al., 2004; Looareesuwan et al., 1992; Sowunmi et al., 2007; Barennes et al., 
2004; Faye et al., 2007; Van Vugt et al., 2002; Kofoed et al., 2003; Bich et al., 1996; Li et al., 
1984; Kayentao et al., 2009; Carmona-Fonseca et al., 2008). In three trials which employed 
more than two interventions, two intervention arms were similar with regards to the drugs 
used, with minor differences in dosages; these were combined into one intervention due to 
their similarity for this review (Gomez et al., 2003; Looareesuwan et al., 1997; Kofoed et al., 
2003). 
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3.1.3.1 Artesunate combined with amodiaquine 
The efficacy of artesunate combined with amodiaquine (AS+AQ) was evaluated in 17 
published and 10 unpublished trials (Table 3.2a and e), in 14 of those AS+AQ was compared 
with artesunate plus sulfadoxine-pyrimethamine (AS+SP). One trial compared the efficacy of 
AS+AQ with that of artesunate plus mefloquine (AS+MQ) and three trials compared AS+AQ 
with artesunate (AS) monotherapy. Artesunate plus methylene-blue (AS+MB), artesunate plus 
chlorproguanil-dapsone (AS+CD) and artesunate plus cotrimoxazole (AS+CT) were 
comparisons for AS+AQ in one trial each. There was one trial evaluating the efficacy of 
adding mefloquine to dihydroartemisinin (DHA) compared to DHA monotherapy (Diem Thuy 
et al., 2007), this and other comparisons are shown in Tables 3.2b-d. Doses for AQ, SP and 
MQ were given over 3 days but there were variations in the duration of AS doses. Artesunate 
was given over three days in all the trials that compared AS+AQ with AS+SP or AS+MQ. 
Contrary to that, a longer duration of seven days was used in one trial for both combination- 
and monotherapy (Sowunmi et al., 2007). On the other hand, artesunate was given for three 
days in both combination and monotherapy in one trial (Barennes et al., 2004). Diem Thuy 
and colleagues (2007) gave two doses of DHA over two days in combination therapy. 
Treatment doses were not described in one trial (Swarthout et al., 2006). All doses were 
supervised but in one trial (Abacassamo et al., 2004), the second and third doses were given at 
home. Data from the included unpublished studies was not complete for this descriptive 
analysis, however, the available data have been presented in Table 3.2e. 
 
3.1.3.2 Artesunate combined with mefloquine 
Artesunate was combined with mefloquine (AS+MQ) in nine trials (Table 3.2b). In four of 
those it was compared with AS monotherapy, with artesunate plus azithromycin (AS+AZ) in 
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one trial, with artesunate plus atovaquone-proguanil (AS+ATV+PRG) in one and with 
artesunate plus mefloqine+sulfadoxine-pyrimethamine (AS+MQ+SP) in one. Artesunate plus 
pyronadine (AS+PR) was a comparison in two unpublished RCTs. Doses for artesunate also 
varied in this comparison. In monotherapy, AS was given for 5-6 days, with the exception of 
two trials in which AS was given for three days (Li et al., 1984; Krudsood et al., 2000). In 
combination therapy, treatment was given for a shorter duration. AS was given as a single 
dose in two trials (Li et al., 1984; Karbwang et al., 1996), while in other trials AS doses were 
given over three days (Gomez et al., 2003; Krudsood et al., 2000; van Vugt et al., 2002; 
Borghini-Fuhrer, unpublished; Rueangweerayut, unpublished). Treatment was given for a 
longer duration in two trials (Looareesuwan et al., 1992; Price et al., 1998), where AS was 
given over five days in combination therapy.  
 
3.1.3.3 Artemisinin or artemether combined with mefloquine 
The other combinations of mefloquine were with artemether (Karbwang et al., 1995; 
Looareesuwan et al., 1997) and with artemisinin (Hassan Alin et al., 1996). These 
combination therapies were compared with AM and A monotherapies, respectively. AM was 
given as a single dose in combination therapy and over five to seven days in monotherapy 
(Table 3.2c).  
 
3.1.3.4 Artesunate or artemisinin monotherapy 
Artesunate monotherapy was used as a control for artesunate plus mefloquine plus 
sulfadoxine-primethamine (AS+MQ+SP) (Li et al., 1984), for artesunate plus chloroquine 
(AS+CQ) (Kofoed et al., 2003), for artesunate plus primaquine (AS+PQ) (Pukrittayakamee et 
al., 2004) and for artesunate plus azithromycin (AS+AZ) (Krudsood et al., 2000). In addition, 
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artemisinin monotherapy was evaluated against the combination of artemisinin plus beta-
cyclodextrin (A+β-CDX) in one trial (Wong et al., 2003) and one trial evaluated 
dihydroartemisinin (DHA) monotherapy compared to DHA given with mefloquine 
(DHA+MQ) (Dien Thuy et al., 2007) (Table 3.2c).  
 
The duration of treatment with artemisinin derivatives was three days for both combination 
and monotherapy in two trials (Kofoed et al., 2003; Krudsood et al., 2000), five days in one 
trial (Wong et al., 2003) and seven days in another (Pukrittayakamee et al., 2004). In another 
trial, monotherapy was given over three days and combination therapy was given as a single 
dose (Li et al., 1984). 
 
 3.1.3.5 Other combinations 
Artesunate was combined with chloroquine (AS+CQ) and compared to artesunate plus 
sulfadoxine-pyrimethamine (AS+SP) in one trial (Huong et al., 2003). Other interventiosn 
compared with AS+SP were artesunate plus sulfadoxine-pyrimethamine plus primaquine 
(AS+SP+PQ) (Shekalaghe et al., 2007) and artesunate plus sulfamethoxypyrimethamine 
(AS+SMP). One RCT compared artemisinin plus quinine (A+Q) with artemisinin plus 
doxycycline (A+D) (Bich et al., 1996) and artemether plus doxycycline (AM+D) was 
compared with artemether plus azithromycin (AM+AZ) in one trial (Table 3.2d) (Na-
Bangchang et al., 1996). In one trial (Huong et al., 2003), artesunate doses were given over 
three days in both treatment arms while in another, artemisinin treatment was a single dose in 
both treatment arms (Bich et al., 1997). A single dose of artemether was given in the AM+AZ 
treatment arm while the other participants in the treatment group received AM over five days 
(Na-Bangchang et al., 1996).  
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3.1.4 Length of follow-up 
The length of follow-up was 28 days for these RCTs, but in one RCT (Abacassamo et al., 
2004) a follow-up of 21 days was reported while the reported results were up to the 14th day 
of follow-up. In another RCT, the length of follow-up was 28 days but treatment failure rates 
were up to 21 days (Sowunmi et al., 2007). The two trials were not excluded since the length 
of foloow-up was not listed as the exclusion criteria and results for some outcomes, like early 
treatment failure and fever clearance times could be obtained irrespective of the length of 
follow-up. In one RCT (Faye et al., 2007), there were no participants lost to follow-up at dat 
28, however, 30% of participants were followed up for 42 days.  Five of the trials that gave 
MQ followed up for 42 days (Diem Thuy et al., 2007; Karbwang et al., 1995; 1996; Price et 
al., 1998; Van Vugt et al., 2002). The duration of follow-up was 35 days in two trials (Kofoed 
et al., 2003; Wong et al., 2003).  
 
3.1.5 Outcomes 
3.1.5.1 Analyzed outcomes 
Ten of the RCTs that reported treatment failure excluded new infections detected with the 
polymerase chain reaction (PCR) (Bonnet et al., 2007; Djimde et al., 2008; Fehintola et al.,  
2008; Guthman et al., 2005; Hamour et al., 2005; Kayentao et al., 2009; Owusu-Agyeyi et al.,  
2008; Swarhout et al., 2006; Van den Broek et al., 2006;  Zoungrana et al., 2008) while in two 
RCTs patients were admitted to health facilities for the duration of follow-up (Looareesuwan 
et al., 1992; 1997). This method was also used to exclude the possibility of re-infection in 
patients who were treated, thus these were also categorized as true treatment failure. When 
new infections were excluded, treatment failure was reported as adjusted treatment failure. If 
re-infections were not excluded, unadjusted treatment failure was reported. In other RCTs, re-
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infections were not excluded in treatment failure. Events of early treatment failure were 
reported in four RCTs (Bonnet et al., 2007; Guthman et al., 2005; Owusu-Agyeyi et al., 2008; 
Kayentao et al., 2009).  
 
Eleven trials reported both fever and parasite clearance times in hours (Barennes et al., 2007; 
Bich et al., 1996; Diem Thuy et al., 2007; Fehintola et al., 2008; Huong et al., 2000; Sowunmi 
et al., 2007; Li et al., 1984; Looareesuwan et al., 1992; 1997; Krudsood et al., 2000; Wong et 
al., 2003), while Pukrittayakamee and colleagues (2004) reported only parasite clearance time 
in hours. Two trials also reported time taken to clear 50% and 90% of parasites (PCT 50 and 
PCT 90, respectively) (Bich et al.,  1996; Diem Thuy et al., 2007). There were also three trials 
that reported parasite clearance at day 3 (Bonnet et al., 2007; Hamour et al., 2005; Kayentao et 
al., 2009). Only two trials reported anaemia on day 28 (Guthman et al., 2005; Kayentao et al., 
2009). Gametocyte carriage was reported at day 7 in two trials (Shekalaghe et al., 2007; 
Owusu-Agyeyi et al., 2008), at day 14 in three (Guthman et al., 2005; Hamour et al., 2005; 
Owusu-Agyeyi et al., 2008) and at day 28 in three trials as well (Bonnet et al., 2007; Guthman 
et al., 2005; Hamour et al., 2005). 
 
3.1.5.2 Other reported outcomes 
In addition to the outcomes reported above, there were other outcomes that were analyzed in 
trials but not reported in this review. These include clinical failure at day 21 (Faye et al., 2007) 
parasite reduction ratios on day two and gametocyte carriage after treatment (Sowunmi et al., 
2007). Parasitaemia on day one and decrease in heamatocrit values (%) were reported in one 
trial (Barennes et al., 2004) whereas one trial (Van Vugt et al., 2002) reported the decrease in 
heamatocrit values on day seven (%) and gametocyte carriage in person-gametocyte 
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weeks/1000 person-weeks. One trial reported a 60-day cure rate (Gomez et al., 2003) and 
another one reported parasitaemia on day two and day 35 (Kofoed et al., 2003). Lastly, 
clearance of 95% of the baseline parasites burden (PCT 95) was reported in one trial (Li et al., 
1984).  
With an indication that other outcomes were assessed but not adequately reported, additional 
data were sought from the authors. The requested data were: 
• Fever clearance time, presence of fever on day three, anaemia on day 28 and gametocyte 
carriage at day 14 (Abacassamo et al., 2004).  
• Gametocyte carriage on days 14 and 28 (Guthmann et al., 2005). 
• Parasite clearance time of 90% of the baseline burden (Looareesuwan et al., 1992). 
• Fever and parasite clearance time (Na-Bangchang et al., 1996). 
• Cure rates for the AS and AS+PQ treatment groups and the number of patients with 
gametocyte appearances (Pukrittayakamee et al., 2004). 
• Proportions of patients who cleared fever on day two or who had fever on day three, 
gametocyte carriage on day 14 and anaemia on day 28 in (Van den Broek et al., 2006), 
and  
• Anaemia at day 28 (Swarthout et al., 2006). 
 
Data were successfully obtained from Guthmann et al., (2005). 
 
3.1.5.3 Adverse events 
Most of the trials did not adequately and systematically reported adverse events and side 
effects, however, there were ten trials adequately reporting adverse events and comparing the 
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different intervention arms (Bich et al., 1996; Djimde et al., 2008; Karbwang et al., 1995; 
1996; Li et al., 1984; Looareesuwan et al., 1992; Na-Bangchang et al., 1996; Price et al., 
1998; Van Vugt et al., 2002; Zoungrana et al., 2008). 
 
3.2 Methodological quality of studies that were included  
3.2.1 Generation of the sequence used to allocate participants into different groups 
All 37 trials were reported as randomized. Only eight RCTs reported methods to generate the 
allocation sequence that were likely to be free of bias. These included a random permuted 
block method (Abacassamo et al., 2004; Swarthout et al., 2006; Diem Thuy et al., 2008) and 
computer generated codes (Bich et al., 1996; Barennes et al., 2004; Shekalaghe et al., 2007; 
Owusu-Agyeyi et al., 2008; Zoungrana et al., 2008). In one RCT, randomization started only 
after the 30th patient was enrolled (Guthmann et al., 2005) which is likely to have introduced 
bias. The rest of the RCTs were not clear on the methods used to generate the allocation 
sequence. Table 3.3 shows the methodological quality of included studies.  
 
3.2.2 Concealment of the allocation sequence before allocating participants into groups 
The methods used to conceal the allocation sequence were likely to be free of bias in eight 
RCTs; these were sealed and numbered envelopes containing the treatment code (Table 3.3). It 
was, however, not stated whether the envelopes were opaque or not (Swarthout et al., 2006; 
Van Vugt et al., 2002; Bich et al., 1996; Abacassamo et al., 2004; Diem Thuy et al., 2007; 
Harmour et al., 2005; Kofoed et al., 2003; Zoungrana et al., 2008). In three RCTs, it was 
stated that the envelopes were opened or drawn only after informed consent was given or after 
inclusion (Van Vugt et al., 2002; Swarthout et al., 2006; Bich et al., 1996). In two RCTs, the 
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allocation sequence was reported as not concealed (Guthmann et al., 2005; Bonnet et al., 
























Table 3.3: Methodological quality of the studies that were included.* 
 
Reference Generation of 
allocation sequence 






Abacassamo  et al., 2004 Random permutted 
block method 
Sealed envelopes Open  13 11 
Barenness  et al., 2004 Computer generated Unclear Participants, care givers 
and outcome assessors 
0 0 
Bich  et al., 1996 Computer generated Envelopes drawn after 
inclusion  
Open  2.2 7.5 
Bonnet  et al., 2007 Unclear Not concealed Unclear 2.7 3.6 
Carmona-Fonsecca et al., 
2008 
Unclear Unclear Unclear 0 0 
Diem Thuy et al., 2007 Codes in blocks of 4 Sealed and numbered 
envelopes 
Open 0 0 
Djimde et al., 2008 Unclear Unclear Unclear 1.6 3.6  & 1.6 
Faye  et al., 2007 Unclear  Unclear Open  0 0 
Fehintola et al., 2008 Unclear  Unclear Unclear 0 0 
Gomez  et al., 2003 Unclear Unclear Unclear 0 0 
Guthmann  et al., 2005 Started after 30th Not concealed  
patient 
Unclear 13 7 
Hamour  et al., 2005 Unclear Sealed envelopes Unclear 0 2.5 
Hassan Alin  et al., 1996 Unclear Unclear Outcome assessor  15 5.5 
Huong  et al., 2003 Unclear Unclear Unclear 0 0 
Owusu-Agyei et al., 2008 Computer generated Unclear Unclear 2.9 2.9 
Karbwang  et al., 1995 Unclear Unclear Unclear 10.7 5.7 
Karbwang  et al., 1996 Unclear Unclear Unclear  17.6 7 
Kayento et al., 2009 Unclear Unclear Participants and 
outcome assessors 
1.5 1.5 
Kofoed  et al., 2003 Unclear Sealed envelopes Unclear 21.3 11.3 
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Table 3.3 (continued): Methodological quality of the studies that were included* 
 
*Two unpublished and included RCTs had no data on methodological quality 
 
 










Krudsood  et al., 2000 Unclear Unclear Unclear 18.9 10.3 
Li  et al., 1984 Unclear Unclear Unclear 0 0 
Looareesuwan  et al., 1992 Unclear Unclear Unclear 7.1 4.8 
Looareesuwan et al., 1997 Unclear Unclear Open  17 11.2 
Na-Bangchang  et al., 1996 Unclear Unclear Unclear 0 10 
Price  et al., 1998 Unclear Unclear Open  2 0 
Pukrittayakamee  et al., 2004 Unclear Unclear Unclear 7.4 8.7 
Rulise et al.,  2007 Unclear Unclear Open 5.8% replaced 3.7% replaced 
Shekalaghe et al., 2007 Computer generated Unclear All staff 1.9 1.9 
Sowunmi  et al., 2007 Unclear Unclear Unclear 0 7.5 
Sowunmi et al., 2009 Unclear Unclear Unclear 15 3.3 
Swarthout  et al., 2006 Computer generated Envelopes drawn after 
inclusion 
Outcome assessor  7.7 10 
Van den Broek  et al., 2006 Unclear Unclear Unclear 4 4.6 
Van Vugt  et al., 2002 Unclear Envelopes drawn after 
inclusion 
Open  0 0 
Wong  et al., 2003 Unclear Unclear Outcome assessor  0 0 
Zoungrana et al., 2008 Computer generated Sealed envelopes Outcome assessors 0 1.6 
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3.2.3 Blinding of research personnel and participants to allocated interventions 
Participants, care-givers and outcome assessors were blinded to the study treatments in one 
RCT (Barennes et al., 2004) and in one RCT, all research staff were blinded but there was no 
mention of blinding the patients though it is likely that they were blinded as well (Shekalaghe 
et al., 2007). Four RCTs blinded only the outcome assessors (Swarthout et al., 2006; Hassan 
Alin et al., 1996 and Wong et al., 2003; Zoungrana et al., 2008). Authors of seven RCTs 
(Abacassamo et al., 2004; Diem Thuy et al., 2007; Faye et al., 2007; Bich et al., 199; 
Looareesuwan et al., 1997; Price et al., 1998; Van Vugt et al., 2002; Rulise et al., 2007) 
reported not blinding participants and care-givers. The rest of the studies did not describe 
blinding (Table 3.3). 
 
3.2.4 Inclusion of all randomized participants in the assessment of outcomes 
In nine RCTs, all randomized participants were included in the analysis (Barennes et al., 2004; 
Diem Thuy et al., 2007; Faye et al., 2007; Fehintola et al., 2008; Gomez et al., 2003; Huong et 
al., 2003; Li et al., 1984; Van Vugt et al., 2002; Wong et al., 2003). The inclusion of 
randomized participants in the analysis was more than or equal to 90% in 19 trials and seven 
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Bonnet et al., 2007 
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3.3 The efficacy and safety of different treatments 
3.3.1 Artesunate plus amodiaquine combination therapy 
3.3.1.1 Treatment Failure 
Adjusted treatment failure at day 28 was reported in seven trials comparing AS+AQ with 
AS+SP (Figure 3.2). Treatment with AS+AQ was associated with a 43% lower risk of 
adjusted treatment failure compared to AS+SP (RR=0.57, 95% CI [0.33, 0.97], p=0.04, 7 
trials, N= 1341).  
    AS = artesunate, AQ = amodiaquine, SP = sulfadoxine-pyrimethamine, CI = confidence interval 
 
Figure 3.2: The risk of treatment failure in patients when artesunate plus amodiaquine 




The risk of early treatment failure was lower in AS+AQ (RR=0.26, 95% CI [0.04, 1.59], 
P=0.15; 3 trials, N= 658), however, the difference between treatments was not statistically 
significant. With regards to the risk of re-infection there was tremendous heterogeneity 
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between the RCTs, with two RCTs conducted in Mali significantly in favour of AS+SP 
(Djimde et al., 2008; Kayentao et al., 2009). In other RCTs in the DRC and in Guinea, there 
was no significant difference observed between the two treatment groups. Due to this level of 
heterogeneity (I2
 
= 83%, p<0.0001), it was not correct to combine data in a meta-analysis.  The 
potential sources of heterogeneity between these five trials were explored; even though these 
RCTs were conducted in areas with SP resistance, resistance in Mali is lower than in the DRC 
(Djimde et al., 2008; Swarthout et al., 2006). 
Compared to AS+CD and AS+MB, AS+AQ had a significantly lower risk of adjusted 
treatment failure but there was no statistically significant difference when compared to 
AS+CT (Table 3.4). Furthermore, treatment with AS+AQ was significantly associated with a 
lower risk of re-infection compared to other combination therapies, with the exception of 
AS+MQ, which showed no significant difference (Table 3.5).  
 
 
Table 3.4: Adjusted treatment failure at day 28 when artesunate plus amodiaquine was 
compared with other combination therapies or artesunate monotherapy. 
 







Fehintola et al., 2008  AS+CT 4/61 11/121 0.72 (0.24, 2.17) 0.31 
Owusu-Agyeyi et al., 2008 AS+CD 11/149 25/147 0.43 (0.22, 0.85) 0.01 
Zoungrana  et al., 2008  AS+MB 11/61 22/60 0.49 (0.26, 0.92) 0.03 
Djimde et al., 2008  AS 1/114 4/115 0.25 (0.03, 2.22) 0.21 
 
AS= artesunate, CT= cotrimoxazole, CD= chlorproguanil-dapsone, MB= methylene-blue n= number of patients 





Table 3.5: The risk of re-infection when artesunate plus amodiaquine was compared with other 
combination therapies or artesunate monotherapy. 
 







Fehintola et al., 2008 AS+CT 2/61 22/121 0.18 (0.04, 0.74) 0.02 
Owusu-Agyeyi et al., 2008 AS+CD 11/148 23/144 0.47 (0.24, 0.92) 0.03 
Zoungrana  et al., 2008 AS+MB 10/61 21/60 0.47 (0.24, 0.91) 0.03 
Faye et al., 2007  AS+MQ 9/360 3/145 1.21 (0.33, 4.40) 0.77 
Djimde et al., 2008 AS 18/114 44/115 0.41 (0.25, 0.67) <0.001 
 
AS= artesunate, CT= cotrimoxazole, CD= chlorproguanil-dapsone, MB= methylene-blue, MQ= Mefloquine,  n= 
number of patients reporting an outcome, N= total number of patients examined, CI= confidence interval 
 
In one trial comparing AS+AQ with AS monotherapy, there was a 95% lower risk of PCR 
unadjusted treatment failure at day 21 in AS+AQ (RR= 0.05, 95% CI [0.01, 0.34], p=0.002; 
N=231).  
 
3.3.1.2 Fever clearance time 
Two trials reported the number of patients who cleared fever on day two, there was no 
statistically significant difference between AS+AQ and AS+SP (RR=1.03, 95% CI [0.09, 
1.08], p= 0.32; 1 trial, N=161), and between AS+AQ and AS monotherapy (RR=0.92, 95% CI 
[0.75, 1.13], p=0.44; 1 trial, N=60). Another trial reported the number of patients who were 
still febrile at day three when treated with AS+AQ compared to AS+SP, and there was no 
statistically significant difference between the two treatments (RR=0.67, 95% CI [0.15, 2.91], 
p= 0.59; N=191). When AS+AQ was compared to AS monotherapy, two trials reported fever 
clearance time in hours. Treatment with AS+AQ was significantly quicker in clearing fever 
compared to AS monotherapy, however, there was no statistically significant difference when 
AS+AQ was compared to AS+CT (Figure 3.3).  
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3.3.1.3 Parasite clearance time 
Three studies reported the number of patients who cleared parasitaemia at day three, 
comparing AS+AQ with AS+SP. In both treatments, most patients cleared parasitaemia 
showing no statistically significant difference between treatments (RR=1.01, 95% CI [0.96, 
1.07], p=0.58; N=649). Two trials that compared AS+AQ with AS monotherapy reported the 
time taken to clear parasitaemia in hours. These showed no difference between treatments. 
However, when AS+AQ was compared with AS+CT, AS+AQ was significantly slower in 
clearing parasitaemia (Figure 3.4).  
 
AS= artesunate, AQ= amodiaquine, CT= cotrimoxazole, SD= standard deviation, CI= confidence interval  
 
Figure 3.3: Fever clearance time (hours) in patients treated with artesunate plus amodiaquine, 
artesunate plus cotrimoxazole or with artesunate monotherapy. 
 
Study or Subgroup 
AS+AQ vs AS+CT 
Fehintola et al. 2008 
Test for overall effect: Z = 0.98 (P = 0.33) 
AS+AQ vs AS monotherapy 
Barennes et al. 2004 
Sowunmi et al. 2007 
Subtotal (95% CI) 
Heterogeneity: Chi² = 0.39, df = 1 (P = 0.53); I² = 0% 
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 70 
AS= artesunate, AQ= amodiaquine, CT= cotrimoxazole, SD=standard deviation, CI= confidence interval  
 
Figure 3.4: Parasite clearance time (hours) in patients treated with artesunate plus 
amodiaquine, artesunate plus cotrimoxazole or with artesunate monotherapy. 
Study or Subgroup 
AS+AQ vs AS+CT 
Fehintola et al. 2008  
Test for overall effect: Z = 5.76 (P < 0.00001) 
AS+AQ vs AS monotherapy 
Barennes et al. 2004 
Sowunmi et al. 2007 
Subtotal (95% CI) 
Heterogeneity: Tau² = 0.00; Chi² = 0.00, df = 1 (P = 1.00); I² = 0% 
































IV, Random, 95% CI 
13.16 [8.68, 17.64] 
0.00 [-0.61, 0.61] 
0.00 [-3.35, 3.35] 
0.00 [-0.60, 0.60] 
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3.3.1.4 Anaemia at day 28 
There were two RCTs reporting the number of patients with anaemia at day 28, although the risk of 
having anaemia was slightly lower in patients treated with AS+AQ compared to AS+SP, there was 
no statistically significant difference between the two treatments (RR=0.95, 95% CI [0.79, 1.14], 
p=0.46; N=429). 
 
3.3.1.5 Gametocyte carriage at days 7, 14 and 28 
Gametocyte carriage at day seven, 14 and 28 was reported in one, two and three trials, respectively 
(Figure 3.5).  
 
AS=artesunate, AQ= amodiaquine, SP=sulfadoxine-pyrimethamine, CD= chlorproguanil-dapsone, CI= confidence interval  
 
Figure 3.5: Gametocyte carriage at days 7, 14 and 28 in patients treated with artesunate plus 
amodiaquine, artesunate plus sulfadoxine-pyrimethamine or artesunate plus chlorproguanil-
dapsone.  
Study or Subgroup 
Gametocyte carriage at day 7: AS+AQ vs AS+CD 
Owusu-Agyei et al. 2008 
Test for overall effect: Z = 0.91 (P = 0.36) 
Gametocyte carriage at day 14: AS+AQ vs AS+SP 
Guthmann et al. 2005 
Hamour et al. 2005 
Subtotal (95% CI) 
Total events 
Heterogeneity: Chi² = 1.69, df = 1 (P = 0.19); I² = 41% 
Test for overall effect: Z = 1.25 (P = 0.21) 
Gametocyte carriage at day 28: AS+AQ vs AS+SP 
Bonnet  et al. 2007 
Guthmann et al. 2005 
Hamour et al. 2005 
Subtotal (95% CI) 
Total events 
Heterogeneity: Chi² = 0.39, df = 2 (P = 0.82); I² = 0% 
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Treatment with AS+AQ was associated with a lower risk of gametocyte carriage at days seven 
compared to AS+CD, whereas the risk of gametocyte carriage at days 14 and 28 was greater in 
AS+AQ compared to treatment with AS+SP. There was, however, no statistically significant 
difference between the treatments. 
 
3.3.1.6 Adverse events and side effects 
The most commonly cited side effect in all treatments was repeated dose vomiting or vomiting 
(Hamour et al., 2005; Sowunmi et al., 2007; Guthman et al., 2005; Ibrahium et al., 2007; Owusu-
Ayei et al., 2008; Djimde et al., 2008; Van den Broek et al., 2006; Faye et al., 2007; Zoungrana et 
al., 2008). In one trial a patient treated with AS+AQ was hospitalized due to severe vomiting 
(Zoungrana et al., 2008). A statistically significant difference in the risk of inducing vomiting was 
observed when AS+AQ was compared to AS+MB (Zoungrana et al., 2008) with a 64% lower risk 
in AS+AQ (RR=0.36, 95% CI [0.23, 0.57], p≤0.001; 1 trial n=122). Other common side effects 
associated with the digestive system included nausea, diarrhoea, inability to suck or drink, loss of 
appetite, anorexia, ulcers and mild gastralgia, with no difference in their frequency between 
treatment groups in all trials.  
 
Pruritus was the most common dermatological side effect in patients treated with AS+AQ, AS+SP, 
AS+MQ, AS+CD or AS monotherapy (Sowunmi et al., 2007; Owusu-Agyei et al., 2008; 
Zoungrana et al., 2008). In other trials urticaria, skin itching, macopapular rash, asthenia, dysuria, 
bronchitis, difficulty in breathing, body pains, joint pains and abdominal pain were also reported. 
Dizziness was reported in patients treated with AS+AQ, AS+SP or AS+MQ (Ibrahium et al., 2007; 
Faye et al., 2007). Other common side effects associated with the nervous system included 
headache and difficulties in sleeping (Owusi-Agyei et al., 2008; Zoungrana et al., 2008).  
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One patient treated with AS+AQ had febrile convulsions at day 16 and in the same trial, 
biochemical analysis revealed a transient increase in alanine aminotransferase (ALAT) at day 28 in 
one patient treated with AS+SP (Barennes et al., 2004). In another trial a patient treated with 
AS+SP had a slight increase in creatinine levels (Faye et al., 2007). One trial reported the risk of 
grade 1 ALAT toxicity and abnormal ALAT during follow-up, when comparing AS+AQ with 
AS+SP or AS monotherapy (Djimde et al., 2008). The risk of grade 1 ALAT toxicity was four 
times greater in AS+AQ compared to AS+SP (RR=4.03, 95% [1.17, 13.94], p=0.03, 1 trial, N=149) 
but there was no significant difference when AS+AQ was compared with AS monotherapy.  
Abnormal ALAT during follow-up was three times greater in ASAQ compared to AS+SP and AS 
monotherapy, and the difference between treatments was at the borderline of statistical significance. 










3.3.2 Artesunate plus mefloquine combination therapy 
3.3.2.1 Treatment failure 
Treatment failure at day 28 was reported in six trials comparing AS+MQ with AS 
monotherapy. Treatment with AS+MQ was significantly associated with a 66% lower risk of 
PCR unadjusted treatment failure compared to AS monotherapy (Figure 3.6). However, there 
was no significant difference in adjusted treatment failure between the two treatments 
(RR=0.09, 95% CI [0.01, 1.63], p=0.1, one trial, N=79).  
  
AS= artesunate, MQ = mefloquine, CI = confidence interval 
 
Figure 3.6: The risk of unadjusted treatment failure in patients when artesunate plus 
mefloquine combination therapy was compared with artesunate monotherapy. 
 
In one trial comparing AS+MQ with AS+AZ, the risk of PCR unadjusted treatment failure at 
day 28 was 96% lower in AS+MQ. Another trial comparing AS+MQ with AS+ATV+PRG 
reported treatment failure at day 42, the risk of PCR unadjusted treatment failure in AS+MQ 
was almost twice the risk in AS+ATV+PRG, and when re-infections were separated with 
recrudescences, no statistically significant difference was observed in the risk of adjusted 
treatment failure between AS+MQ and AS+ATV+PRG (Table 3.6). 
Study or Subgroup 
AS+MQ vs AS 
Gomez et al., 2003 
Karbwang et al., 1996 
Krudsood et al., 2000 
Li et al., 1984 
Looareesuwan et al., 1992 
Price et al., 1998 
Subtotal (95% CI) 
Total events 
Heterogeneity: Chi² = 15.55, df = 5 (P = 0.008); I² = 68% 
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0.33 [0.19, 0.56] 
AS+MQ Control Risk Ratio Risk Ratio 
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0.001 0.1 1 10 1000 
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Table 3.6: The risk of treatment failure when artesunate plus mefloquine combination therapy 
was compared with artesunate plus azithromycin or artesunate plus atovaquone plus proguanil. 
Reference Comparison Outcome Number of patients  RR (95% CI) p-value 





Krudsood et al., 2000 AS+AZ 
Unadjusted treatment 
failure at day 28 
0/27 12/27 0.04 (0.00, 0.64) 0.02 
Van Vugt et al., 2002 AS+ATV+PRG 
Unadjusted treatment 
failure at day 42 
35/533 18/533 1.94 (1.12, 3.39) 0.02 
Van Vugt et al., 2002 AS+ATV+PRG 
Adjusted treatment failure 
at day 42 
13/533 5/533 2.60 (0.93, 7.24) 0.07 
 
AS= artesunate, ATV= atovaquone, PRG= proguanil, MQ= mefloquine 
n= number of patients with an outcome, N= number of patients examined, RR= relative risk, CI= confidence 
interval 
 
3.3.2.2 Fever clearance time 
Fever clearance time was longer with AS+MQ by 3.76 hours compared to AS monotherapy, 
by 5.2 hours compared to AS+AZ and by 8.4 hours compared to artesunate plus mefloquine 
plus sulfadoxine-pyrimethamine (AS+MQ+SP), but the difference between treatments was not 
statistically significant (Figure 3.7). Most patients cleared fever on day two when comparing 
AS+MQ with AS+ATV+PRG and the difference between these two treatments was 








AS = artesunate, MQ = mefloquine, AZ = azithromycin, SP = sulfadoxine-pyrimethamine 
n= number of patients with an outcome, N= number of patients examined, SD= standard deviation, CI= confidence interval, WMD= weighted mean difference  
 
Figure 3.7: Fever clearance time when artesunate plus mefloquine was compared with artesunate monotherapy, artesunate plus 
azithromycin or artesunate plus mefloquine plus sulfadoxine-pyrimethamine. 
Comparisons  AS+MQ  Control  WMD (fixed)  Weight  WMD (fixed) 
or references N Mean (SD) N Mean (SD)  95% CI  %  95% CI 
AS+MQ vs AS 
Li et al., 1984                  10     22.00(12.90)          9     15.50(11.00)      39.99      6.50 [-4.25, 17.25]       
Looareesuwan et al., 1992       39     37.50(24.60)         40     35.10(23.40)      41.19      2.40 [-8.19, 12.99]       
Krudsood et al., 2000            28     38.80(32.10)         31     37.90(29.00)      18.82      0.90 [-14.77, 16.57]      
Subtotal (95% CI)     77                          80 100.00      3.76 [-3.04, 10.56] 
Test for heterogeneity: Chi² = 0.44, df = 2 (P = 0.80), I² = 0% 
Test for overall effect: Z = 1.08 (P = 0.28) 
AS+MQ vs AS+AZ 
Krudsood et al., 2000            27     38.80(32.10)         28     33.60(27.20)     100.00      5.20 [-10.55, 20.95]      
Test for overall effect: Z = 0.65 (P = 0.52) 
AS+MQ vs AS+MQ+SP 
Li et al., 1984                  10     22.00(12.90)         10     13.60(11.60)     100.00      8.40 [-2.35, 19.15]       
Test for overall effect: Z = 1.53 (P = 0.13) 
 -100  -50  0  50  100 
 Favours AS+MQ  Favours Control 
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Table 3.7: The number of patients who cleared fever and parasites at the given times when 
artesunate plus mefloquine combination therapy was compared with artesunate plus 
atovaquone plus proguanil. 
 
 
AS= artesunate, ATV= atovaquone, PRG= proguanil, MQ= mefloquine 
n= number of patients with an outcome, N= number of patients examined, RR= relative risk, CI= confidence 
interval 
 
3.3.2.3 Parasite clearance time 
The time taken to clear parasites was not significantly different when AS+MQ was compared 
with AS monotherapy (WMD=-0.09, 95% CI [-1.43, 1.26], p=0.9), or with AS+AZ 
(WMD=1.80, 95% CI [-6.67, 10.27], p=0.68) and with AS+MQ+SP (WMD=5.2, 95% CI [-
10.76, 21.16], p=0.52 (Figure 3.8). However, more patients cleared parasitaemia on day three 
when treated with AS+MQ compared to AS+ATV+PRG (Table 3.7). 
Reference Comparison Outcome Number of patients  RR (95% CI) p-value 





Van Vugt et al., 2002 AS+ATV+PRG Fever on day 2 6/533 15/533 0.40 (0.16, 1.02) 0.06 
Van Vugt et al., 2002 AS+ATV+PRG 
Parasite clearance 
on day 3 
531/533 511/533 1.04 (1.02, 1.06) <0.001 
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AS= artesunate, MQ= mefloquine, AZ= azithromycin, SP= sulfadoxine-pyrimethamine, N= number of patients examined, SD= standard deviation, WMD= 
weighted mean difference, CI= confidence interval  
 
 
Figure 3.8: Parasite clearance time in patients treated with artesunate plus mefloquine or other treatments.
Comparisons  AS+MQ  Control  WMD (fixed)  Weight  WMD (fixed) 
or references N Mean (SD) N Mean (SD)  95% CI  %  95% CI 
AS+MQ vs AS 
Li et al., 1984                  10     60.10(22.40)          9     44.70(13.00)       0.68     15.40 [-0.88, 31.68]       
Looareesuwan et al., 1992       39     37.50(10.30)         40     35.90(10.10)       8.94      1.60 [-2.90, 6.10]        
Krudsood et al., 2000            28     45.30(14.70)         31     43.70(13.60)       3.44      1.60 [-5.65, 8.85]        
Gomez et al., 2003              100      8.75(4.15)          50      9.20(4.30)       86.93     -0.45 [-1.89, 0.99]        
Subtotal (95% CI)    177                         130 100.00     -0.09 [-1.43, 1.26] 
Test for heterogeneity: Chi² = 4.47, df = 3 (P = 0.22), I² = 32.9% 
Test for overall effect: Z = 0.13 (P = 0.90) 
AS+MQ vs AS+AZ 
Krudsood et al., 2000            27     45.30(14.70)         28     43.50(17.30)     100.00      1.80 [-6.67, 10.27]       
Test for overall effect: Z = 0.42 (P = 0.68) 
AS+MQ vs AS+MQ+SP 
Li et al., 1984                  10     60.10(22.40)         10     54.90(12.70)     100.00      5.20 [-10.76, 21.16]      
Test for overall effect: Z = 0.64 (P = 0.52) 
 -100  -50  0  50  100 
 Favours AS+MQ  Favours Control 
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3.3.2.4 Adverse events and side effects 
There was no statistically significant difference in the risk of developing dizziness, diarrhea, 
nausea and vomiting in patients treated with AS+MQ compared to AS monotherapy (Table 
3.8) (Looareesuwan et al., 1992; Karbwang et al., 1996; Li et al., 1984; Price et al., 1998).  
 











Three Dizziness 6/126 8/124 0.76 (0.29, 2.00) 0.58 









1.37 (0.72, 2.59) 
0.33 (0.05, 2.07) 
0.58 
0.24 
AS= artesunate, MQ= mefloquine, n= number of patients reporting an outcome, N= number of patients assessed, 
CI= confidence interval 
 
In other trials, abdominal pain was reported in two patients treated with AS+MQ and two with 
AS monotherapy (Looareesuwan et al., 1992; Li et al., 1984). There was one report of 
heamoglobinuria in a patient treated with AS+MQ (Price et al., 1998). Elevated transaminase 
enzymes were reported in two patients treated with AS+MQ and six treated with AS 
monotherapy. There was no statistically significant difference in the risk of enzyme increase 
between the two treatments (RR=0.31, 95% CI [0.07, 1.44], p=0.14, 1 trial, N=66) (Karbwang 
et al., 1996).  The risk of developing headache (RR=0.86, 95% CI [0.45, 1.63], p=0.64) and 
skin itching with rash (RR=0.33, 95% CI [0.04, 3.08], p=0.33) was lower in patients treated 
with AS+MQ compared to AS monotherapy, but the difference between these treatments was 
not statistically significant (Looareesuwan et al., 1992).  
 80 
In one trial, there was a significantly increased risk of vomiting within one hour in patients 
treated with AS+ATV+PRG (RR=0.11, 95% CI [0.01, 0.87], p=0.04, N=1066) compared to 
AS+MQ. Contrary to that, the risk of nausea at days one and two was significantly greater in 
patients treated with AS+MQ (RR=1.92, 95% CI [1.26, 2.93], p=0.003, N=664). Although the 
difference between treatments was not statistically significant, the risk of vomiting after one 
hour (RR= 1.26, 95% CI [0.85, 1.86], p=0.24, N=817) and of chills and rigors on days one and 
two (RR=1.03, 95% CI [0.64, 1.65], p=0.92, N=589) was a higher in patients treated with 


















3.3.3 Other artemisinin derivatives plus mefloquine combination therapy 
3.3.3.1 Treatment failure 
Treatment with AM+MQ was significantly associated with less unadjusted treatment failure 
when compared with AM monotherapy. However, when re-infections were excluded, the 
difference in the risk of treatment failure was not statistically significant. Treatments with 
A+MQ and A monotherapy were also not significantly different in reducing the risk of 
unadjusted treatment failure (Table 3.9).  
 
Table 3.9: The risk of treatment failure when artemethe plus mefloquine combination therapy 
was compared with artemether monotherapy and when artemisinin plus mefloquine was 
compared with artemisinin monotherapy. 
Reference Intervention Control Outcome Number of patients RR (95% CI) p-
value 
    Intervention 
(n/N)   
Control 
(n/N)   
  
Karbwang et al., 1995; 
Looareesuwan et al., 1997 
AM+MQ AM UTF 4/94 17/137 0.32 (0.11, 0.98) 0.05 
Looareesuwan et al., 1997 AM+MQ AM ATF 1/44 11/87 1.08 (0.02, 1.35) 0.1 
Hassan Alin et al., 1996 A+MQ A UTF 0/17 7/17 0.07 (0.00, 1.08) 0.06 
 
AM= artemether, A= artesunate, MQ= mefloquine, UTF= unadjusted treatment failure, ATF= adjusted treatment 
failure, n= number of patients with an outcome, N= number of patients examined, RR= relative risk, CI= 
confidence interval 
 
3.3.3.2 Fever clearance time 
There was no statistically significant difference in reducing the time to fever clearance 
between treatments with AM+MQ and AM monotherapy (WMD=0.9, 95% CI [-5.84, 7.64)], 
p=0.79, 1 trial N=131) and between DHA+MQ and DHA monotherapy (WMD=2.9, 95% CI [-
4.14, 9.94], p=0.42), 1 trial, N=89).  
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3.3.3.3 Parasite clearance time 
Although patients treated with AM+MQ cleared parasites 3.7 hours earlier than patients 
treated with AM monotherapy, the difference between treatments was not statistically 
significant (WMD= -3.70, 95% CI [-7.57, 0.17], p=0.06, 1 trial, N=131). Adding mefloquine 
to DHA had no additional benefit in PCT as there was no significant difference when 
compared with DHA monotherapy (WMD=2.5, 95% CI [-5.12, 10.12], p=0.52, 1 trial, N=89). 
Clearance of 50% of the burden of parasitaemia (PCT50) was also not statistically different 
comparing DHA+MQ and DHA monotherapy, though slightly in favour of combination 
therapy (WMD=-0.4, 95% CI [-3.00, 2.20], p=0.76, 1 trial, N=89).  
 
3.3.3.4 Adverse events and side effects 
One patient treated with A+MQ reported restlessness, dysphoria, lack of concentration and 
insomnia. In the same trial, two patients treated with artemisinin monotherapy reported skin 
itching which appeared one week after treatment and disappeared after two weeks (Hassan 
Alin et al., 1996). In another trial, headache, dizziness, nausea, vomiting, abdominal pain and 
diarrhoea were reported but with no specifications about the treatment given and the number 
of patients reporting such events (Looareesuwan et al., 1997). When AM+MQ was compared 
with AM monotherapy in one trial, there was a higher risk of vomiting and dizziness in 
patients treated with AM+MQ, on the other hand, the risk of nausea was higher in patients 
treated with AM monotherapy. Nevertheless, there was no statistically significant difference 




Table 3.10: The risk of side effects in patients treated with artemether plus mefloquine or with 
artemether monotherapy. 







Karbwang et al 1995 Nausea 7/56 7/53 0.95 (0.36, 2.52) 0.91 
Karbwang et al 1995 Vomiting 9/56 3/53 2.84 (0.81, 9.92) 0.1 
Karbwang et al 1995 Dizziness 13/56 6/53 2.05 (0.84, 5.00) 0.11 
AM= artemether, MQ= mefloquine, n= nimber of patients reporting an outcome, N= number of patients 
evaluated, CI= confidence interval. 
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3.3.4 Artesunate and artemisinin monotherapy 
3.3.4.1 Treatment failure 
There was no statistically significant difference in reducing the risk of unadjusted treatment 
failure when AS+MQ+SP, AS+CQ, AS+AZ and AS+PQ were compared with AS 
monotherapy (Table 3.11).  
 
Table 3.11: The risk of unadjusted treatment failure when different combination therapies 
were compared with artesunate monotherapy. 
 
AS = artesunate, MQ = mefloquine, SP = sulfadoxine-pyrimethamine, CQ = chloroquine, PQ = primaquine,  
AZ = azithromycin, n = number of patients with an outcome, N = number of patients examined, RR= relative 
risk, CI = confidence interval 
 
3.3.4.2 Fever clearance time 
Treatment with A+ß-CDX was associated with a significantly decreased fever clearance time 
compared to artemisinin monotherapy. This maybe attributed to the ability of ß-CDX to 
increase the solubility of artemisinins in water (Illapakurthy et al., 2010), but there was no 
statistically significant difference when AS+MQ+SP and AS+AZ were compared with AS 




Reference Comparison Number of patients RR (95% CI) p-value 
  Treatment (n/N) 
AS 
 (n/N)   
Li et al., 1984 AS+MQ+SP 0/10 3/8 0.12 (0.01, 1.98) 0.14 
Kofoed et al., 2003 AS+CQ 15/180 10/72 0.60 (0.28, 1.27) 0.18 
Pukrittayakamme et al., 2004 AS+PQ 4/25 2/21 1.68 (0.34, 8.28) 0.52 
Kroodsood et al., 2000 AS+AZ 12/28 17/30 0.76 (0.45, 1.28) 0.30 
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3.3.4.3 Parasite clearance time 
Artemisinin monotherapy was quicker than A+ß-CDX in clearing parasites but AS+MQ+SP, 
AS+AZ and AS+PQ were not significantly different to AS monotherapy (Table 3.12b).  
 
3.3.4.4 Adverse events and side effects 
When AS+MQ+SP was compared with AS monotherapy, two patients treated with 
AS+MQ+SP experienced nausea and one experienced vomiting, with no events reported in 
patients treated with AS monotherapy (Li et al., 1984). In one trial, there were five hospital 
admissions and four of them were due to repeated vomiting. The authors did not report the 
reason for admission of the fifth patient. Four patients were treated with AS+CQ and one was 
treated with AS monotherapy (Kofoed et al., 2003).    
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Table 3.12a: Fever clearance time when patients were given different artemisinin-based treatments. 
 
 
AS= artesunate, A= artemisinin, MQ= mefloquine, SP= sulfadoxine-pyrimethamine, AZ= azithromycin, β-CDX= beta-cyclodextrin, FCT= fever clearance time, 




Table 3.12b: Parasite clearance times when patients were given different artemisinin-based treatments. 
 
AS= artesunate, A= artemisinin, MQ= mefloquine, SP= sulfadoxine-pyrimethamine, AZ= azithromycin, β-CDX= beta-cyclodextrin, PQ= primaquine 
PCT= parasite clearance time, N= number of patients examined, SD= standard deviation, WMD= weighted mean difference, CI= confidence interval, * 
statistically significant at p<0.05 
 
Reference Treatment Control 
Treatment Control 




N Mean (SD) 
(hours) 
Li et al., 1984 AS+MQ+SP AS 10 13.60 (11.60) 8 15.50 (11.00) -1.90 (-12.38, 8.58) 0.72 
Krudsood et al., 2000 AS+AZ AS 27 33.60 (27.20) 30 37.90 (29.00) -4.30 (-18.89, 10.29) 0.56 
Wong et al., 2003 A+β-CDX A 50 17.60 (1.90) 50 21.70 (2.60) -4.10 (-4.99, -3.21) <0.001* 
Reference Treatment Control Treatment Control WMD (95% CI) p-value 




N Mean (SD) 
(hours) 
  
Li et al., 1984 AS+MQ+SP AS 10 54.90 (12.70) 8 44.70 (13.00) 10.20 (-1.76, 22.16) 0.09 
Krudsood et al., 2000 AS+AZ AS 27 43.50 (17.30) 30 43.70 (13.60) -0.20 (-8.34, 7.94) 0.96 
Wong et al., 2003 A+β-CDX A 50 48.70 (2.80) 50 46.60 (2.50) 2.10 (1.06, 3.14) <0.001* 
Pukrittayakamee et al., 2004 AS+PQ AS 27 63.00 (18.00) 27 69.00 (19.00) -6.00 (-16.31, 4.31) 0.25 
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3.3.5 Other combination therapies 
3.3.5.1 Treatment failure 
The combination of A+Q was significantly associated with a 59% lower risk of 
unadjusted treatment failure compared to A+D. On the other hand, the risk of unadjusted 
treatment failure was almost twice as much in AM+AZ when compared to the 
combination of AM+D. Unadjusted treatment failure was significantly higher in AS+CQ 
when compared with AS+SP. No statistically significant difference was observed when 
AS+SP+PQ and AS+SMP were each compared with AS+SP (Table 3.13). When re-
infections were excluded, the difference in risk of adjusted treatment failure between 
AS+CQ and AS+SP was marginally significant, and not statistically significant when 
AS+SP+PQ and AS+SMP were compared with AS+SP (Table 3.13). 
 
Table 3.13: The risk of treatment failure in patients treated with different artemisinin-
based combination therapies. 
Reference Treatment  Control  Outcome Number of patients RR (95% CI) p-value 






Bich et al., 1996 A+Q A+D UTF 9/32 29/42 0.41 (0.23, 0.73) 0.003 
Na-Bangchang et al., 1996 AM+AZ AM+D UTF 23/27 14/30 1.83 (1.21, 2.76) 0.004 
Huong et al., 2003 AS+CQ AS+SP UTF 33/61 21/61 1.57 (1.04, 2.38) 0.03 
Shekalaghe et al., 2007 AS+SP+PQ AS+SP UTF 17/53 15/53 1.13 (0.63, 2.03) 0.67 
Rulisa et al., 2007 AS+SMP AS+SP UTF 11/109 18/103 0.58 (0.29, 1.16) 0.12 
Huong et al., 2003 AS+CQ AS+SP ATF 32/61 21/61 1.52 (1.00, 2.32) 0.05 
Shekalaghe et al., 2007 AS+SP+PQ AS+SP ATF 5/48 2/49 2.55(0.52, 12.52) 0.25 
Rulisa et al., 2007 AS+SMP AS+SP ATF 4/102 10/95 0.37 (0.12, 1.15) 0.09 
AS= artesunate, A= artemisinin, AM= artemether, CQ= chloroquine, Q= quinine, D= doxycycline, AZ= 
azithromycin, SP= sulfadoxine-pyrimethamine, SMP= sulfamethoxy-pyrimethamine, UTF=unadjusted 
treatment failure, ATF= adjusted treatment failure 
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3.3.5.2 Fever clearance time 
The combination of AS+CQ cleared fever significantly quicker than AS+SP with more 
than seven hours (WMD= -7.20, 95% CI [-12.53, -1.87], p= 0.008) whereas there was no 
statistically significant difference in fever clearance time between A+Q and A+D 
(WMD= 3.00, 95% CI [-5.54, 11.54], p= 0.49) (Table 3.14). 
 
3.3.5.3 Parasite clearance time 
Treatment with AS+CQ was associated with a statistically significant shorter parasite 
clearance time of six hours compared to AS+SP (Table 3.14). Both A+Q and A+D were 
equally efficacious in clearing parasites (WMD= 2.00, 95% CI [-4.74, 8.74], p= 0.56) and 
in reducing the density of parasites to 50% of the initial parasitaemia (PCT 50) (WMD=0, 
95% CI [-2.26, 2.26], p=1) as well as to 10% of the initial parasitaemia (PCT 90) 
(WMD= 1.00, 95% CI [-2.15, 4.15], p= 0.53) (Table 3.14). 
 
3.3.5.4 Gametocyte carriage at day 7 and 14 
The risk of carrying gametocytes was significantly reduced by 78% at day 7 and by 94% 
at day 14 when AS+SP+PQ was compared with AS+SP.  The difference between these 
treatments was statistically significant with a p-value <0.001. This comparison was done 






Table 3.14: Fever and parasite clearance times in patients treated with different combination therapies. 
 
A= artemisinin, AS= artesunate, Q= quinine, CQ= chloroquine, D= doxycycline, SP= sulfadoxine-pyrimethamine, FCT= fever clearance time, PCT= parasite 
clearance time, PCT 50= time to clearing 50% of parasite, PCT 90= time to clearing 90% of parasites, N= number of participants assessed, WMD= weighted 





Reference Treatment Control Outcome 
Treatment Control 




N Mean (SD)  
(hours) 
Bich et al., 1996 A+Q A+D FCT 44 34.00 (19.00) 49 31.00 (23.00) 3.00 (-5.54, 11.54) 0.49 
Huong et al., 2000 AS+CQ AS+SP FCT 61 32.40 (13.20) 62 39.60 (16.80) -7.20 (-12.53, -1.87) 0.008* 
Bich et al., 1996 A+Q A+D PCT 44 43.00 (14.00) 49 41.00 (19.00) 2.00 (-4.74, 8.74) 0.56 
Huong et al., 2000 AS+CQ AS+SP PCT 61 40.80 (15.60) 62 46.80 (15.60) -6.00 (-11.51, -0.49) 0.03* 
Bich et al., 1996 A+Q A+D PCT 50 44 9.00 (6.00) 49  9.00 (5.00) 0.00 (-2.26, 2.26) 1 
Bich et al., 1996 A+Q A+D PCT 90 44 18.00 (9.00) 49 17.00 (6.00) 1.00 (-2.15, 4.15) 0.53 
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AS= artesunate, SP= sulfadoxine-pyrimethamine, PQ= primaquine, CI= confidence interval 
 
Figure 3.9: The risk of gametocyte carriage in patients when artesunate plus sulfadoxine-
pyrimethamine plus primaquine was compared with artesunate plus sulfadoxine-
pyrimethamine. 
 
3.3.5.5 Adverse events and side effects 
There was a 75% lower risk of mild nausea, abdominal discomfort and/ or loss of appetite 
in patients treated with AM+AZ compared to the AM+D, (RR=0.25, 95% CI [0.08, 0.80], 
p=0.02 (Na-Bangchang et al., 1996). Although the risk of developing dizziness, tinnitus, 
impaired hearing and dry mouth was higher in patients treated with A+Q was compared 
to A+D, the difference between these two treatments was not statistically significant 




Study or Subgroup 
Gametocyte carriage at baseline 
Shekalaghe et al., 2007 
Test for overall effect: Z = 0.88 (P = 0.38) 
Gametocyte carriageat day 7 
Shekalaghe et al., 2007 
Test for overall effect: Z = 4.52 (P < 0.00001) 
Gametocyte carriage at day 14 
Shekalaghe et al., 2007 





















M-H, Fixed, 95% CI 
1.07 [0.92, 1.23] 
0.22 [0.11, 0.42] 
0.06 [0.02, 0.25] 
AS+SP+PQ AS+SP Risk Ratio Risk Ratio 
M-H, Fixed, 95% CI 
0.01 0.1 1 10 100 
Favours AS+SP+PQ Favours AS+SP 
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Table 3.15: Adverse events and/ or side effects in patients treated with artemisinin plus 
quinine or artemisinin plus doxycycline. 
 
A= artemisinin, Q= quinine, D= doxycycline, RR= relative risk, n= number of patients with an outcome, 















Reference Treatment  Control  Outcome Number of patients RR (95% CI) p-value 






Bich et al., 1996 A+Q A+D Dizziness  4/45 4/53 1.18 (0.31-4.44) 0.81 
Bich et al., 1996 A+Q A+D Tinnitus  5/45 1/53 5.89 (0.71-48.57) 0.10 
Bich et al., 1996 A+Q A+D Impaired hearing 4/45 0/53 10.57 (0.58-191.09) 0.11 
Bich et al., 1996 A+Q A+D Dry mouth 1/45 1/53 1.18 (0.08-18.30) 0.91 
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CHAPTER 4: DISCUSSION 
 
4.1 The challenge of parasite resistance to antimalarials 
Effective case management of malaria is severely crippled by the development and 
spread of parasite resistance to antimalarials. To combat the impact of drug resistance, 
antimalarials with different modes of action are combined. This improves drug efficacy 
and may reverse the impact of drug resistance (Nosten et al., 2000). It also reduces the 
risk of selection for resistant mutants in the plasmodial parasites.  The World Health 
Organization (WHO) now recommends artemisinin-based combination therapy (ACT) 
for the treatment of uncomplicated P. falciparum malaria. The WHO also recommends 
that the cure rates should be at least 90% and preferably ≥95% assessed at 28 days 
(WHO, 2010). Although artemisinins are effective and rapidly acting, their widespread 
use has raised questions with regards to emerging drug resistance (Duffy and Sibley, 
2005). Declining clinical cure rates in patients treated with artemisinins have been 
observed (Vijaykadga et al., 2006; Mey Bouth et al., 2006). Of concern is the 30% PCR 
confirmed recrudescence observed in Cambodia, in patients treated with artemisinin-
monotherapy 21-28 days after treatment.  
 
4.2 Artemisinin-based combination therapy for the treatment of malaria 
Currently recommended ACTs are artemether-lumefantrine, artesunate plus amodiaquine, 
artesunate plus mefloquine and artesunate plus sulfadoxine-pyrimethamine. Artemether-
lumefantrine was the first internationally recognized fixed-dose ACT in use but other 
fixed-dose combinations have later been developed (Nosten and White, 2007). In a recent 
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Cochrane review, dihydroartemisinin-piperaquine has been investigated and it is now 
included in the updated WHO guidelines (Sinclair et al., 2009; WHO, 2010). Other ACTs 
that can possibly be used in the near future include artesunate-chlorproguanil-dapsone, 
artesunate-atovaquone-proguanil and artesunate-pyronaridine (Nosten and White, 2007).  
 
4.3 The focus of the present study 
Several clinical trials have proven the superior efficacy of ACTs compared to non-
artemisinin based regimens (McIntosh and Olliaro, 1999). Reviewing different ACTs, 
there is no consensus on which antimalarial is better suited for combination with the 
various artemisinin derivatives. A Cochrane review (Sinclair et al., 2009) compared 
different ACTs; however, the ACTs have not been evaluated when the same artemisinin 
derivative is combined with different non-artemisinin drugs, thus only evaluating the 
non-artemisinin partner of the combination therapy.  
 
This study, therefore, sought to review the evidence of efficacy and safety of different 
non-artemisinin antimalarials when they are combined with the same artemisinin 
derivative, in reducing the risk of treatment failure in non-pregnant adults and children 
with uncomplicated P. falciparum malaria.  
 
4.4 The findings of this review and the existing knowledge on artemisinin-based 
combination therapy 
The thirty-seven trials with a total of 6862 participants met the inclusion criteria; 21 of 
these RCTs were conducted in Africa, 14 in Asia, and two in South America (Tables 
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3.2a-d). Artesunate was the most commonly used artemisinin derivative in combination 
with antimalarials including amodiaquine, sulfadoxine-pyrimethamine, mefloquine, 
azithromycin and atovaquone-proguanil. Artemether was used in combination with 
mefloquine only. One trial analysed the efficacy of a dihydroartemisinin based 
combination therapy. 
 
4.4.1 The efficacy of artesunate plus amodiaquine combination therapy 
The results show that the efficacy of artesunate combined with amodiaquine was higher 
than the efficacy of artesunate combined with sulfadoxine-pyrimethamine for the 
treatment of uncomplicated P. falciparum malaria. Although there is a possibility of 
cross-resistance between amodiaquine and chloroquine, amoqiaquine has been found to 
be efficacious even in areas of high chloroquine resistance (Van Dillen et al., 1999; 
Brasseur et al., 1999; Staedke et al., 2001). The WHO recommends that artesunate plus 
amodiaquine and artesunate plus sulfadoxine-pyrimethamine can be used in areas where 
the efficacy of their non-artemisinin partner exceeds 80% (WHO, 2010). Prior to this 
review there has been insufficient evidence on the efficacy of artesunate plus 
amodiaquine compared to artesunte plus sulfadoxine-pyrimethamine.  In addition, the 
findings of this review show artesunate plus amodiaquine to be more efficacious than 
artesunate monotherapy. There was only one trial comparing artesunate plus amodiaquine 
with artesunate plus mefloquine (Faye et al., 2007) and there were very few outcomes 
reported while showing no significant difference between the two treatments. 
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Previously, the efficacy of artesunete plus amodiaquine has been evaluated and compared 
with that of artemether-lumefantrine and there was a significantly lower risk of treatment 
failure at day 28 in artemether-lumefantrine given at six doses (Omari et al., 2005). 
However, a recently published Cochrane review showed no significant difference in the 
risk of treatment failure when artemether-lumefantrine was compared with artesunate 
plus amodiaquine (Sinclair et al., 2009). In the unavailability of artemether-lumefantrine 
and considering the requirements of having to consume it with fat-containing foods or 
milk (Muheki et al., 2004; Ashley et al., 2007), which may not be readily available in 
poor communities or house-holds and given the findings of the present study, 
combination therapy with artesunate and amodiaquine should be considered.  
 
The combination of artesunate with amodiaquine is currently available in blister packs as 
separate scored tablets containing 50 mg of artesunate and 153 mg base of amodiaquine 
and its co-formulation has recently been developed. There are no plans for developing a 
fixed dose of artesunate with sulfadoxine-pyrimethamine (Nosten and White, 2007). This 
could be due to the increasing level of resistance to SP and the differing dosage times for 
AS and SP. Artesunate plus sulfadoxine-pyrimethamine is currently being used in parts of 
South America, the Middle East and South Asia, where sulfadoxine-pyrimethamine 
susceptibility remains high. Since sulfadoxine-pyrimethamine, sulfalene–pyrimethamine 
and trimethoprim–sulfamethoxazole (co-trimoxazole) are still widely used as 
monotherapies, resistance is likely to worsen and this is likely to compromise the efficacy 
of ACTs using sulfadoxine-pyrimethamine as a combination antimalarial (Nosten and 
White, 2007).  
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4.4.2 The efficacy of artesunate plus mefloquine combination therapy 
This study showed that artesunate combined with mefloquine was more efficacious 
compared to the combination of artesunate plus azithromycin for the treatment of 
uncomplicated P. falciparum malaria. There is no basis for recommending atovaquone-
proguanil over mefloquine as there were few trials identified comparing them and the 
efficacy of artesunate plus mefloquine and artesunate plus atovaquone-proguanil did not 
differ significantly. This study found that efficacy of artesunate monotherapy was found 
to be low and this is in agreement with previous findings (McIntosh and Olliaro, 1999), 
thus artesunate monotherapy cannot be recommended. Although mefloquine resistance is 
wide-spread and severe in Asia and low levels have been detected in South America 
(Wongsrichanalai et al., 2002), the results showed that the combination of artesunate plus 
mefloquine is still efficacious in these areas.  
 
The WHO recommends artesunate plus mefloquine combination therapy in areas of high 
AQ and SP resistance and when AL is not available (WHO, 2006b). A systematic review 
reported a higher risk of treatment failure on days 28 and 63 with artemether-
lumefantrine given at four doses compared to the combination of artesunate plus 
mefloquine (Omari et al., 2004). It also found that there was no significant difference in 
the risk of treatment failure at day 28 when artemether-lumefantrine at six doses was 
compared to artesunate plus mefloquine. On the other hand, there was a significantly 
higher risk of treatment failure on day 42 with six-dose artemether-lumefatrine compared 
to artesunate plus mefloquine. Artesunate plus mefloquine and six doses of artemether-
lumefantrine seem to have maintained equivalence in a recent Cochrane Review (Sinclair 
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et al., 2009). A fixed dose of artesunate plus mefloquine has been developed and is 
dispensed as tablets containing 200 mg artesunate and 400 mg mefloquine (Nosten and 
White, 2007). The combination of atovaquone-proguanil with artemisinins is not 
recommended due to its high cost, though its safety and efficacy has been proven (WHO, 
2006a).  
 
4.4.3 The use of artemisinins in monotherapy 
With regards to the artemisinin derivatives used in monotherapy, their efficacy has once 
again been confirmed to be very low. In three trials, artesunate monotherapy given over 
three days had failure rates of 13.8-56.7% (Li et al., 1984; Krudsood et al., 2000; Kofoed 
et al., 2003). While artemisinin derivatives used as monotherapy in Thailand given over 
five to seven days had failure rates slightly lower than the 10% recommended by the 
WHO (Karbwang et al., 1995; Looareesuwan et al., 1997; Pukrittayakamee et al., 2004). 
The low efficacy of artemisinin derivatives used in monotherapy was also observed in 
Vietnam and Tanzania with AS monotherapy given for five to seven days (Hassan Alin et 
al., 1996; Giao et al., 2001). Contrary to these observations, polymerase chain reaction 
(PCR) adjusted failure rates in Gabon were 10%, when artesunate monotherapy was 
given for five days (Schwarz et al., 2005).  
 
In the present study, the low efficacy of artesunate monotherapy was not significantly 
different to treatment with artesunate plus mefloquine plus sulfadoxine-pyrimethamine, 
artesunate plus chloroquine, artesunate plus primaquine and artesunate plus azithromycin 
(Li et al., 1984; Krudsood et al., 2000; Kofoed et al., 2003; Pukrittayakamee et al., 
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2004). This can be attributed to a small sample size in one trial (n=60) (Li et al., 1984), 
which does not give enough power to detect the difference between treatments. It is also 
worth noting that in the same trial, AS doses in combination therapy were given for one 
day. In the other trials this may be due to the efficacy of combination treatment being 
similar to that of monotherapy.  
 
4.4.4 The efficacy of ACTs for fever clearance and on gametocytes 
Fever clearance time in hours is the other commonly reported outcome employed for 
assessing the efficacy of treatment. In this analysis, a significant difference was observed 
in favour of artesunate combined with amodiaquine compared to AS monotherapy. 
However, the difference was just more than one hour in this comparison. The clinical 
significance of fever clearance time becomes doubtful when the difference between the 
treatments is just a few hours or less. A difference of more than four hours was observed 
when artemisinin combined with β-cyclodextrin was compared with artemisinin 
monotherapy, in favour of combination therapy (Wong et al., 2003). This maybe due to 
the ability of β-cyclodextrin to increase the solubility of artemisinins in water 
(Illapakurthy et al., 2010). Furthermore, artesunate combined with chloroquine was more 
than seven hours quicker in clearing fever than artesunate combined with sulfadoxine-
pyrimethamine (Huong et al., 2000). The addition of mefloquine to dihydroartemisinin 
did not significantly improve the time taken to clear fever or parasitaemia. In another 
review, fever clearance time did not differ when six-dose artemether-lumefantrine was 
compared with artesunate-mefloquine in a systematic review (Omari et al., 2005).  
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This study also assessed the efficacy of treatment based on its ability to reduce 
gametocyte carriage. Artemisinins have displayed an ability to reduce gametocyte 
carriage by clearing the asexual parasites before they fully develop to gametocytes and by 
their action against matured gametocytes (Guthmann et al., 2005). Treatment that reduces 
gametocyte carriage eventually reduces malaria transmission, especially in low 
transmission areas. Gametocytes persist when the initial burden of parasites is not 
eliminated due to the failure of treatment. The results show that there was no significant 
difference observed in the ability of different therapies to reduce gametocyte carriage, 
although the number of patients who carried gametocytes after treatment was low. 
Treament with primaquine is known to be effective in reducing the risk of gametocytes, 
however, none of the trials that used a combination with primaquine reported gametocyte 
carriage. Omari et al. (2004) made similar observations when comparing six-dose 
artemether-lumefantrine and artesunate plus mefloquine. Therefore, ACTs are equally 
efficacious in reducing gametocyte carriage, and in another study they were even better 
when compared with quinine (Price et al., 1996).  
 
4.5 Limitations and strengths of the study 
While this review clearly identifies antimalarials that can be considered for combination 
with artemisinin derivatives, it is also important to highlight the limitations of the study. 
To assess the efficacy of treatment in high transmission areas, clinical trials should 
exclude new infections using polymerase chain reaction (PCR). Not all the trials reported 
PCR-corrected failure rates and in some of the trials where PCR was performed, not all 
the participants had results available. This could be problematic as it does not give a clear 
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picture of the efficacy of the treatment, in accordance with the WHO recommendations. 
The information on the efficacy of ACTs against new infections is crucial at it will 
inform the policy makers of the effectiveness of the non-artemisinin combination 
antimalarials. The elimination halflife of these antimalarials sustains the effectiveness of 
ACTs against new infections. It should be taken into account, however, that antimalarials 
given in routine settings should be effective even against new infections. Policy makers 
require information on the efficacy of antimalarials against both the initially diagnosed 
infection, and the new infections in high transmission areas. Whenever PCR corrected 
failure rates were reported in trials, they were used in this review. The WHO 
recomendations also emphasize that the antimalarials of choice should be safe, this 
information has not been well presented in these RCTs. The methods of detecting and 
reporting adverse have not been standardized, thus the safety information presented in 
this review is inadequate. Clinical trials are usually not powered enough to detect adverse 
events and the duration of follow-up is short. Nevertheless, this information should be 
properly recorded and presented in a standardized manner.  
 
The duration of follow-up was also not the same between trials but 37 of them had a 
follow-up of 28 days. Most of the mefloquine comparisons had a follow-up of 42 days. 
There were also differences in doses given to participants. In some trials, the duration of 
treatment was shorter than recommended (WHO, 2010), this lead to the high rate of 
treatment failure. The duration of treatment was not stated as the exclusion criteria, thus 
trials that gave artemisinin treatment for shorted durations were not excluded, although 
the short-duration treatment is no recommended. In other trials, artemisinin derivatives 
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were given over five to seven days even in combination therapy and this is likely to have 
over-emphasized the efficacy of ACTs and such long-duration treatments cannot be 
implemented. There is lack of information on two important ACTs; artemether-
lumefantrine and dihydroartemisinin-piperaquine on this review. The two artemisinin 
derivatives, artemether and dihydroartemisinin, have not been evaluated in combination 
with different non-artemisinin antimalarials, thus evaluating only the non-artemisinin 
partner. However, the two ACTs, artemether-lumefantrine and dihydroartemisinin-
piperaquine have been evaluated in a Cochrane review (Sinclair et al., 2009). There was 
also inadequate reporting of the methodology of the trials included in this review, which 
did not allow for the sensitivity analysis in this review. Furthermore, the autors of most 
RCTs did not respond or were unreachable to provide unpublished data.  There is limited 
knowledge with regards to the effects of ACTs on pregnant women and infants, as well as 
on P. vivax malaria.   
 
Nevertheless, evidence presented in this study confirms the efficacy of ACTs for the 
treatment of uncomplicated P. falciparum malaria in non-pregnant adults and children. 
This is inline with WHO recommendations (WHO, 2010). The choice of ACT to be 
implemented in policy recommendations in different settings has been reviewed here. 
Artesunate plus amodiaquine is the combination of choice for Africa over artesunate plus 
sulfadoxine-pyrimethamine and other ACTs evaluated in this review. This ACT has been 
evaluated in ten trials and its efficacy was superior to that of artesunate plus sulfadoxine-
pyrimethamine and artesunate monotherapy. Although artesunate plus amodiaquine was 
not compared with artemether-lumefantrine in this review, a Cochrane review found the 
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two ACTs to be equivalent in efficacy (Sinclair et al., 2009).  Although artesunate plus 
mefloquine is also efficacious, it has not been well researched in Africa. Artesunate plus 
mefloquine is the combination of choice in Asia (Sinclair et al., 2009). The efficacy of 
this combination was high but there was only one trial comparing artesunate plus 
mefloquine with artesunate plus atovaquone-proguanil (Van Vugt et al., 2002), artesunate 
plus azithromycin (Krudsood et al., 2000) and artesunate plus mefloquine plus 
sulfadoxine-pyrimethamine (Li et al., 1984). This review included both the published and 
unpublished studies, however, some of the data obtained from both published and 
unpublished studies was inadequate and the authors of such studies were unreachable. 
There were no language limitations employed in searching for studies. 
 
CONCLUSION  
The findings of this study support the implementation of artemisinin-based combination 
therapy for the treatment of uncomplicated malaria. This work also argues strongly 
against the use of artemisinin-based monotherapy, which has been shown to be associated 
with high rates of treatment failure in this review. Most crucially, this review found a 
greater advantage of combining amodiaquine with artesunate compared to sulfadoxine-
pyrimethamine. Treatment with artesunate plus amodiaquine should also be considered in 
situation where artemether-lumefantrine is not convenient. The efficacy of artesunate plus 
mefloquine was also superior to that of artesunate plus azithromycin. Furthermore, the 
combination of artemisinins with chloroquine, primaquine and azithromycin has shown 
very low efficacy and these combination therapies should not be recommended.  
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Artesunate plus atovaquone-proguanil needs to be further investigated globally. In 
addition, a more detailed description of the methods used in clinical trials is suggested. 
Investigators need to implement a more vigorous approach in generating and concealing 
the allocation sequence, in blinding the participants, care givers and outcome assessors. 
This lowers the chances of bias in clinical trials (Higgins and Altman, 2008). These trials 
were not designed to investigate adverse events as there was no systematic reporting of 
such events. This raises a need for clinical trials to consider the safety of different 
combination therapies and to uniformly collect data regarding adverse events. 
 
In this review, the efficacy of ACTs has been confirmed in agreement with present 
recommendations, systematic reviews and previous trials (WHO, 2006b; Sinclair et al., 
2009). Furthermore, the potential antimalarials for combination with different artemisinin 
derivatives have also been identified as well as antimalarials that are not suitable for 
combination with artemisinins. This was done by collating findings of different 
randomized controlled trials performed in different settings globally. The methods used 
in this study enable the determination of consistencies and variations in available 
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APENDIX A: Search strategy 
The following databases were searched using the search terms and strategy described 
in Table 01.  
• Cochrane Central Register of Controlled Trials (CENTRAL), published in The  
Cochrane Library, 2008; Issue 4 
• MEDLINE (1966 to January 2009).  





h set CENTRAL MEDLINE** EMBASE** 
1 malaria malaria Malaria  
2 Plasmodium Plasmodium Plasmodium 
3 1 or 2 1 or 2 1 or 2 
4 artemisinin artemisinin artemisinin 
5 artesunate artesunate artesunate 
6 artemether artemether artemether 
7 arteether arteether arteether 
8 dyhydroartemisinin dyhydroartemisinin dyhydroartemisinin 
9 4 or 5 or 6 or 7 or 8 4 or 5 or 6 or 7 or 8 4 or 5 or 6 or 7 or 8 
10 3 and 9 3 and 9 3 and 9 
  Limit 10 to human Limit 10 to human 
**Search terms for malaria were used in combination with the search 
strategy for retrieving trials developed by The Cochrane Collaboration, 
described in: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic 
Reviews of Interventions Version 5.0.1 [updated September 2008]. The Cochrane 




APPENDIX B.1: STUDY ELIGIBILITY FORM  
Date:  
Extractor (initials):  
Trial ID:  
Trial Name:  
Journal:  
(1) Design 
(a) Described as randomized? 
If ‘No’, exclude. If ‘Yes’, go to question (2) 
Yes       No      Unclear 
(Circle) 
(2) Participants 
(a) Did the participants have microscopically confirmed P. falciparum 
malaria?  
Yes       No      Unclear 
(Circle) 
(b) Did the participants have uncomplicated malaria? Yes       No      Unclear 
(Circle) 
If (a) or (b) answer ‘No’, exclude. If ‘Yes’ go to question (3)  
(3) Interventions 
(a) Was one group given an ACT as treatment? Yes       No      Unclear (Circle) 
(b) Did another group receive an alternative ACT or monotherapy 
with the same artemisinin derivative? 
Yes       No      Unclear (Circle) 
If (a) or (b) answer ‘No’, exclude. If ‘Yes’ go to question (4)  
(4) Outcomes 
Did the trial report any of the following outcomes?   
(a) Treatment failures Yes       No      Unclear (Circle) 
(b) Fever clearance time Yes       No      Unclear (Circle) 
(c) Parasite clearance time Yes       No      Unclear (Circle) 
(d) Measure of anaemia Yes       No      Unclear (Circle) 
(e) Measure of gametocytaemia Yes       No      Unclear (Circle) 
(f) Adverse events Yes       No      Unclear (Circle) 
If all (a) to (f) answer ‘No’, exclude.  
Final Decision 
Include  Yes       No (Circle) 
Exclude Yes       No (Circle) 
Unclear Yes       No (Circle) 
Excluded or unclear because: 
 





APPENDIX B.2: METHODOLOGICAL QUALITY FORM  
Date:  
Extractor (initials):  
Trial ID:  
Trial Name:  
Journal:  
(1) Sequence generation 
Method:    
 
Reviewers judgement:     Adequate            Inadequate            Unclear              (circle) 
(2) Allocation concealment 
Method:    
 
Reviewers judgement:      Adequate            Inadequate            Unclear              (circle) 
(3) Blinding of participants, personnel and outcome assessors 
Description:    
 
 
Reviewers judgement:     Adequate            Inadequate            Unclear              (circle) 
(4) Loss to follow-up 
Description:    
 
 
Reviewers judgement:     All included         More than 90%       Less than 90%     Unclear       (circle) 
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APPENDIX B.3: DATA EXTRACTION FORM A- CHARACTERISTICS OF STUDIES 
Date:  
Extractor (initials):  
Trial ID:  
Trial Name:  
Journal:  
Trial details 
Trial Dates (from-to: dd/mm/yyyy):   
Country:  
Setting (urban/rural/hosp/clinic):           
Malaria transmission pattern:  
Local antimalarial drug resistance:  
Frequency and duration of follow-up: 
Include details of activity at each 
follow up visit e.g. temp/blood slide/ 








































Characteristics: Group 1:  Group 2: Group 3: 
Sex ratio (Male:Female):    
Age Range (years/months):    
Mean/Median age (years/months):    
Body Weight (kg) mean/median:    
Haemoglobin (g/dl) mean/median:    
Were all treatment groups comparable 
at baseline? 
If ‘No/unclear’ Describe: 






 Treatment Group 1:  
 
Treatment Group 2: Treatment Group 3: 
Antimalarial 1:    
Formulation:    
Timing and frequency of dose:    
Duration:    
Total dose (target):    
Antimalarial 2:    
Formulation:    
Timing and frequency of dose:    
Duration:    
Total dose (target):    
Treatment supervised? Yes           No           Unclear            (circle) 
Dosing details: 
Weight based or age based? 
Tablets or suspension? 











APPENDIX B.3: DATA EXTRACTION FORM B- OUTCOMES REPORTED  
Date:  
Extractor (initials):  
Trial ID:  
Trial Name:  
Journal:  
Participants with/without outcomes: 
 Group 1:  Group 2: Group 3: 
Participants randomised:    
Participants with no treatment 
Outcome (total): 
   
• Excluded after randomisation    
• Lost to follow up    





Early Treatment Failure    
Late Treatment failure: day 28 (n/N) 
• PCR unadjusted failure    
• PCR confirmed recrudescence    
• Re-infection    
• PCR indeterminate    
Late Treatment failure: day 42 (n/N) 
• PCR unadjusted failure    
• PCR confirmed recrudescence    
• Re-infection    













 Group 1:  Group 2: Group 3: 
Fever clearance 
Fever clearance time (hrs) 
(N: mean ±SD) 
   
Fever on day 2 (n/N)    
Fever on day 3 (n/N)    
Parasite clearance 
Parasite clearance time (hrs) 
(N: mean ±SD 
   
PCT 50 (N: mean ±SD    
PCT 90 (N: mean ±SD    
Parasite clearance at day 2 (n/N)    
Parasite clearance at day 3 (n/N)    
Parasite clearance at day 7 (n/N)    
Parasite clearance at day 14 (n/N)    
Parasite clearance at day 21 (n/N)    
Parasite clearance at day 28 (n/N)    
Gametocyte carriage (n/N) 
Gametocyte carriage at baseline    
Gametocyte carriage at day 7     
Gametocyte carriage at day 14     
Gametocyte carriage at day 28    
Anaemia 

























Adverse events  
 Group 1:  
 
Group 2: Group 3: 
    
    
    
    










   
Other important information 


























E-mail:   
Telephone:  












APPENDIX C: INTERVENTIONS AND OUTCOMES 
 
Appendix C.1: Adjusted treatment failure 
Outcome: Adjusted 
treatment failure 
Interventions and results 
Reference AS+AQ AS+SP AS+MQ AS+ATV+PRG AS+CT AS+CD AS+MB AM+MQ AS+CQ AS+SP+PQ AS+SMP AS AM 
Bonnet et al 2007 1/107 1/106                       
Djimde 2008 2/229 0/229                   8/231   
Guthman 2005 1/83 1/84                       
Hamour 2005 4/72 5/71                       
Kayentao 2009 6/131 6/130                       
Swarthout 2006 5/83 13/79                       
Van den Broek 2006 1/84 7/80                       
Looaresuwan 1992     0/39                 5/40   
Van Vugt 2002     13/533 5/533                   
Looaresuwan 1997               1/44         11/87 
Huong 2003   21/61             32/61         
Shekalaghe 2007   4/49               5/48       
Rulisa 2007   10/95                 4/102     
Fehintola 2008 4/61       11/121                 
Owusu-Agyeyi 2008 11/149         25/147               










Interventions and results 
Reference AS+AQ AS+SP AS+MQ AS+ATV+PRG AS+CT AS+CD AM+MQ AS+PQ AS+CQ 
Bonnet et al 2007 6/107 7/100               
Carona-Fonseca 0/52 2/98               
Djimde 2008 44/235 12/232               
Hamour 2005 29/80 27/79               
Kayentao 2009 58/131 12/130               
Swarthout 2006 14/83 28/81               
Van den Broek 2006 31/97 21/85               
Looaresuwan 1992     0/39             
Van Vugt 2002     35/533 18/533           
Looaresuwan 1997             1/44     
Huong 2003   21/61       33/61       
Shekalaghe 2007   15/53               
Rulisa 2007   18/103               
Fehintola 2008 6/61       33/121         
Owusu-Agyeyi 2008 22/150         45/157       
Zoungrana 2008 21/61           43/60     
Gomez 2003     5/100             
Karbwang 1995             3/50     
Karbwang 1996     6/28             
Krudsood 2000     1/55             
Li 1982     0/20             
Price 1998     2/34             
Koefoed 2003                 38/229 
Pukrittayakamee 2004               4/25   
Bich 1996                   
Na-Bangchang 1996                   
Faye 2007 3/145   9/360             





Appendix C.2 (table continued): Un-adjusted treatment failure 
 
Outcome: Un-adjusted 
treatment failure  
Interventions and results 
Reference AS+SP+PQ AS+MQ+SP AS+SMP AS+AZ AM+AZ A+Q A+D AM+D AS AM 
Bonnet et al 2007                     
Carona-Fonseca                     
Djimde 2008                 99/234   
Hamour 2005                     
Kayentao 2009                     
Swarthout 2006                     
Van den Broek 2006                     
Looaresuwan 1992                 5/40   
Van Vugt 2002                     
Looaresuwan 1997                   11/87 
Huong 2003                     
Shekalaghe 2007 17/53                   
Rulisa 2007     11/109               
Fehintola 2008                     
Owusu-Agyeyi 2008                     
Zoungrana 2008                     
Gomez 2003                 12/150   
Karbwang 1995                   6/50 
Karbwang 1996                 2/31   
Krudsood 2000       24/55         34/61   
Li 1982   0/20             7/17   
Price 1998                     
Koefoed 2003                 45/112   
Pukrittayakamee 2004                 2/21   
Bich 1996           9/32 29/42       
Na-Bangchang 1996         23/27     14/30     
Faye 2007                     






Appendix C.3: Re-infection 
  
Outcome: Re-infection Interventions and results 
Reference AS+AQ AS+SP AS+MQ AS+ATV+PRG AS+CT AS+CD AS+MB AS+CQ AS+SP+PQ AS+SMP AS 
Bonnet et al 2007 5/107 7/106                   
Djimde 2008 37/229 9/229                 88/231 
Hamour 2005 17/72 14/71                   
Kayentao 2009 52/131 6/128                   
Swarthout 2006 9/83 13/79                   
Van den Broek 2006 17/84 9/80                   
Van Vugt 2002     22/533 13/533               
Huong 2003   0/62           1/61       
Shekalaghe 2007   9/49             7/48     
Rulisa 2007   8/103               7/109   
Fehintola 2008 2/61       22/121             
Owusu-Agyeyi 2008 11/148         23/144           
Zoungrana 2008 10/61           21/60         









Appendix C.4: Fever and parasite clearance times (hours) 
Outcome: Fever and parasite clearance times Interventions and results 
DHA+MQ DHA AS+AQ AS+CT AS 
Reference Outcome N mean SD N mean SD N mean SD N mean SD       
Barennes 2004 Fever clearance time             33 38.4 1.68       27 39.6 1.68 
Barennes 2004 Parasite clearance time             33 27.2 1.2       27 27.2 1.2 
Fehintola 2008 Parasite clearance time             61 44.6 15.84 120 31.44 11.52       
Fehintola 2008 Fever clearance time             61 28.8 14.4 121 31.2 17.6       
Sowunmi 2007 Fever clearance time             120 24 14.4       120 24 14.4 
Sowunmi 2007 Parasite clearance time             120 33.6 14.4       120 33.6 12 
Diem Thuy 2007 Parasite clearance time 44 37.8 19.2 45 35.3 17.4                   
Diem Thuy 2007 Parasite clearance time 50 44 7.9 5.3 45 8.3 7.1                   












Appendix C.5: Other outcomes 
Outcomes Reference Interventions and results 
Early treatment failure   AS+AQ AS+SP AS+CD AS+SP+PQ AS+MQ AS+ATV+PRG AS 
Bonnet et al 2007 0/107 1/106  
    Guthman 2005 0/97 1/87  
    Kayentao 2009 0/131 2/130  
    Owusu-Agyeyi 2008 1/151   3/160         
Anaemia at day 28 Guthman 2005 33/84 31/84           
Kayentao 2009 71/131 78/130           
Gametocytes at day 7 Shekalaghe 2007   38/53   8/51       
Owusu-Agyeyi 2008 3/151   6/160         
Gametocytes at day 14 Guthman 2005 12/84 5/84           
Hamour 2005 3/80 4/79 
 
 
   Shekalaghe 2007   32/51   2/51       
Gametocytes at day 28 Bonnet et al 2007 4/106 2/101           
Guthman 2005 1/84 0/84 
     Hamour 2005 2/68 2/70           
Parasite clearance at day 3 Bonnet et al 2007 105/110 103/117           
Hamour 2005 79/80 80/81 
     Kayentao 2009 129/131 129/130           
Fever clearance at day 2 Barennes 2004 27/33           24/27 
Hamour 2005 79/80 78/81 
  
   
Van Vugt 2002         527/533 518/533   
Fever at day 3 Van den Broek 2006 3/101 4/90           
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TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.   
ABSTRACT   
Structured summary  2 Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; 
study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.  
 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.   
Objectives  4 Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design 
(PICOS).  
 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including 
registration number.  
 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as 
criteria for eligibility, giving rationale.  
 
Information sources  7 Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and 
date last searched.  
 
Search  8 Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.   
Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).   
Data collection process  10 Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data 
from investigators.  
 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.   
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), 
and how this information is to be used in any data synthesis.  
 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).   
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2  ) for each meta-analysis.  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).   
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.   
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RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow 
diagram.  
 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.   
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).   
Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and 
confidence intervals, ideally with a forest plot.  
 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.   
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).   
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).   
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare 
providers, users, and policy makers).  
 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).   
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future research.   
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.   
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